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          Adipose tissue serves as the primary storage depot for excess calories in mammals 
and its normal development and the efficient storage and release triglycerides are 
necessary to maintain systemic metabolism. Well studied factors that shape the 
development and metabolic function of adipose tissue include anabolic hormones, e.g. 
insulin and glucocorticoids, and circulating catabolic factors, e.g. glucagon and 
catecholamines. Less well defined are the roles of local factors that shape adipose tissue 
development and function. Here we have studied the role of locally produced insulin-like 
growth factor-1 (IGF1) on adipose tissue development and lipolysis. We found that 
expression of Igf1 by adipose tissue is derived from multiple cell types including 
adipocytes and macrophages. The expression of adipose tissue Igf1 is maintained at a 
constant level during the development of obesity despite the large influx of macrophages.  
This occurs because as adipocytes undergo hypertrophy their expression of Igf1 is 
reduced.    
          Targeted deletion of Igf1 from adipocytes, macrophages or both cells reveals that 
adipocyte-derived IGF1 is required for hyperplasia of adipocytes in intra-abdominal but 
not subcutaneous depots during the development of obesity and that macrophage-derived  
IGF1 maintains adipose tissue mass of intra-abdominal fat during a thermogenic 
challenge. We did not detect any systemic metabolic effect of cell-specific deletion of  
Igf1 but found evidence of fibrosis in livers of obese mice that lack myeloid IGF1.  
	  	  	  
	  
	  
           As an independent study, we investigated the role of lipolysis in lipid uptake by 
adipose tissue macrophages (ATMs). We previously reported that lipolysis regulates 
ATM recruitment to fat. In addition, a recent study revealed that ATMs accumulate 
neutral lipid and contribute to adipose tissue metabolism by activating lysosomal-
dependent program. However, in obese mice neutral lipids accumulate in membrane 
bound vesicles, i.e. not lipid droplets. This raises the possibility that neutral lipids 
accumulate in ATMs in a lipolysis independent manner, through a process of 
endocytosis. To address whether lipid uptake in ATM is dependent upon adipocyte 
lipolysis, we generated mice that lacked the neutral lipase required for adipocyte lipolysis 
(PNPLA2/ATGL). Adipocyte-specific deletion of Pnpla2 markedly reduced the 
accumulation of lipid in ATMs from lean and obese mice arguing that adipose PNPLA2-
dependent lipolysis modulates ATM lipid uptake in both lean and obese animals.   
 These findings argue that local interactions among cell populations in adipose 
tissue are important in regulating both development and metabolic function of adipose 
tissue mass, and that more detailed studies of the paracrine interactions offer the 
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Chapter 1: Introduction 
1.1 Obesity, Inflammation, and Insulin Resistance  
  Obesity is a global health problem causing an increasing clinical burden due to 
associated complications, including type 2 diabetes, atherosclerosis, non-alcoholic fatty 
liver disease (NAFLD), obstructive sleep apnea and several types of cancers 
(Hotamisligil, 2006). Obesity-induced inflammation is characterized by elevation of 
circulatory levels of both pro-inflammatory cytokines and acute-phase proteins including 
TNF-α, IL-6, C-Reactive Protein (CRP), fibrinogen and serum amyloid (Kershaw & 
Flier, 2004). The chronic low-grade inflammation induced by obesity is also described as 
infiltration of myeloid immune cells into multiple tissues (Lumeng & Saltiel, 2011; 
Wellen & Hotamisligil, 2005). The infiltrated macrophages secret pro-inflammatory 
cytokines and exacerbate stress signaling in adipose tissue, liver, skeletal muscle and 
hypothalamus (Lumeng & Saltiel, 2011). Thus, the chronic inflammation has important 
role in the link between obesity and multiple diseases with immune responses in the 
related tissues (Lumeng & Saltiel, 2011).  
      Several molecular signaling pathways link inflammation with altered metabolism 
(Arkan et al., 2005; Lumeng & Saltiel, 2011; Wellen & Hotamisligil, 2005). It has been 
shown that inflammation contributes to metabolic dysfunction, in particular insulin 
resistance, via activation of several serine/threonine kinases that inhibit downstream of 
insulin signaling (Hotamisligil, 2006). Among the kinases implicated in inhibition of 
insulin action are Janus kinases (JNK1 & JNK2), protein kinase C isoforms and inhibitor 
of kappaB kinase beta (IKBKB), each of which directly phosphorylates insulin receptor 




2005). In obesity JNK is activated by ER stress, cytokines, and fatty acids and impairs 
insulin action by phosphorylating serine residue of IRS1 (Wellen & Hotamisligil, 2005). 
Consistently, genetic ablation of JNK1 in mice reduces obesity–induced JNK activation, 
IRS1 serine phosphorylation, and, consequently, insulin resistance in liver, muscle and 
adipose tissue (Hirosumi et al., 2002). Unlike JNK1, although JNK2 deletion in mice 
showed no metabolic phenotype, haplodeficiency of JNK1 in JNK2 deleted mice 
demonstrated that lack of JNK2 is compensated by induction of JNK1 activity (Hirosumi 
et al., 2002; Tuncman et al., 2006). Therefore, optimum balance of JNK1 and JNK2 
activity is essential in insulin signaling. 
PKC (PKC -delta and -theta) also has a critical role in inhibiting insulin activation 
through lipid signaling (Boden et al., 2005; Yu et al., 2002). It has been previously shown 
that fatty acid metabolites activate PKC theta (Prkcq) and PKC delta (Prkcd) in muscle 
and liver respectively and reduce insulin signaling in rats (Boden et al., 2005; Yu et al., 
2002). Consistently, PRKCQ deficient mice were protected from fatty acid-induced 
insulin resistance in skeletal muscle (Kim et al., 2004). In addition, genetic ablation of 
PRKCD in mice improved hepatic insulin resistance and liver-specific overexpression of 
Prkcd induced hepatic steatosis (Bezy et al., 2011). Taken together, PRKCQ and PRKCD 
regulate insulin signaling in both skeletal muscle and liver.  
IKBKB is another kinase that impairs insulin activation by phosphorylating serine 
residues of IRS-1 (Gao et al., 2002) and by phosphorylating inhibitor of NF-kB (IkB) 
thereby activating transcription of inflammatory genes (Wellen & Hotamisligil, 2005). 
Mice that are heterozygous for IKBKB were partially protected from insulin resistance 




by high dose treatment of salicylates improved insulin action in both mouse models and 
humans (Fleischman, Shoelson, Bernier, & Goldfine, 2008; Hundal et al., 2002; Yuan et 
al., 2001). Furthermore, hepatic activation of IKBKB induced local and systemic insulin 
resistance (Cai et al., 2005). In contrast, myeloid deletion of IKBKB enhanced glucose 
homeostasis during high fat feeding (Arkan et al., 2005). Therefore, IKBKB modulates 
local and systemic insulin signaling in obesity-induced inflammation. Overall, obesity is 
characterized as increased production of inflammatory molecules, which affects 
intracellular insulin pathways in metabolically important tissues.  
 
1.2 Adipose Tissue Macrophages (ATMs) in Obesity 
   In 1993, Hotamisligil and colleagues discovered that a pro-inflammatory 
molecule, tumor necrosis factor (TNF previously known as TNF-α), is produced by 
adipose tissue from obese individuals and in a series of genetic and neutralization 
experiments implicated TNF in the development of obesity-induced systemic insulin 
resistance (Hotamisligil, Shargill, & Spiegelman, 1993). IL-6 is also an inflammatory 
cytokine and secreted by adipose tissue from obese subjects (Fried, Bunkin, & 
Greenberg, 1998). A human weight loss study with obese individuals showed that 
circulating concentration of IL-6 is correlated with body mass index (BMI) and insulin 
resistance (Bastard et al., 2000; Fried, Bunkin, & Greenberg, 1998). Additionally, plasma 
monocyte chemoattractant protein-1 (MCP1) concentration is directly correlated with 
body weight, which is released by both adipocytes and monocytes in adipose tissue from 
obese rodents (Sartipy & Loskutoff, 2003; Takahashi et al., 2003). Plasminogen activator 




involved in obesity-induced insulin resistance (Juhan-Vague, Alessi, Mavri, & Morange, 
2003). Hence, in obesity various pro-inflammatory proteins are derived from adipose 
tissue, which are released into circulation and eventually contribute to systemic insulin 
resistance. 
Ten years later, two independent groups, Weisberg and colleagues and Xu and 
colleagues found that obesity is accompanied by macrophage infiltration in adipose 
tissue, which contributes significantly to obesity-induced inflammation (Weisberg et al., 
2003; H. Xu et al., 2003). Consistent with these initial observations, several subsequent 
studies showed that the recruited adipose tissue macrophages (ATMs) produce pro-
inflammatory molecules implicated in obesity-induced metabolic dysfunction including 
TNF-α, IL-6, IL-1β, MCP-1, and osteopontin (Weisberg et al., 2006; Weisberg et al., 
2003; H. Xu et al., 2003). The ATM- derived inflammatory molecules exacerbate the 
chronic-low grade inflammation by interrupting insulin signaling in metabolic tissues and 
eventually cause systemic glucose intolerance (Chawla, Nguyen, & Goh, 2011; Lumeng 
& Saltiel, 2011). During the development of obesity ATM recruitment is regulated by 
several factors. Since adipose tissue undergoes dynamic changes and remodeling in 
obesity, lipid overloading, adipocyte death, hypoxia-induced fibrosis, chemotactic 
secretion, and increase in local free fatty-acids (FFAs) flux occur during the massive 
adipose tissue expansion (Sun, Kusminski, & Scherer, 2011). In another words, as 
adipose tissue expands, the disrupted homeostasis in fat induces macrophages infiltration 
in response to dead adipocytes, adipocyte-derived chemotactic molecules, and excess 
lipids (Sun et al., 2011). Thus, ATM recruitment is regulated by many factors that are 




      In Latin “macrophage” means “big eater;” a name that accurately describes a key 
function of macrophages. They eat among other things foreign pathogens, protein 
aggregates, lipids, and dead cells (Herwald & Egesten, 2013). Obesity increases the 
number of dead adipocytes and ATMs accumulate at dead adipocyte forming so-called 
crown-like structures (CLS) (Cinti et al., 2005). CLS and ATM accumulation are also 
noted in several non-obese states. In hormone-sensitive lipase (HSL) deficient mice, a 
non-obese mouse model of adipocyte hypertrophy, CLS are also found (Cinti et al., 
2005). Direct evidence for ATM clearance of dead adipocytes and associated lipid debris 
is found in models of lipodystrophy. Pajvani and colleagues found ATM accumulate in 
an inducible adipocyte-specific apoptosis mouse model, FAT-ATTAC mice, after the 
treatment of apoptotic dimer, AP20187 (Pajvani et al., 2005). Similarly, Herrero and 
colleagues observed both apoptotic adipocytes and CLS in white and brown adipose 
tissue of aP2-nSREBP-1c transgenic lipodystrophic mice (Herrero, Shapiro, Nayer, Lee, 
& Shoelson, 2010). 
     Pathological adipose tissue expansion not only leads to necrotic- and apoptotic-cell 
deaths, but also creates areas of local hypoxia (Sun et al., 2011). As the adipocytes 
increase their volume, the vascular expansion has been proposed not to accommodate this 
expansion and create pockets of low oxygen tension in adipose tissue of obese 
individuals. Several studies found that hypoxia induces macrophage recruitment and 
chronic inflammation in adipose tissue of both obese mice and humans (Halberg et al., 
2009; Y. S. Lee et al., 2014; O'Rourke et al., 2011; Ye, Gao, Yin, & He, 2007). Ye et al. 
directly measured the partial pressure of oxygen in adipose tissue of obese leptin-




al., 2007). Obesity also increases hypoxia-related gene expression in tight association 
with macrophage-specific and inflammatory gene expression (Ye et al., 2007). More 
direct evidence of hypoxia-induced local inflammation was shown in human HIF-1α 
adipocyte-specific overexpressing transgenic mice, in which increased fibrosis followed 
by macrophage infiltration in adipose tissue were observed (Halberg et al., 2009). 
Conversely, adipocyte-specific HIF-1α knockout (KO) mice resulted decrease in 
macrophage accumulation with reduced pro-inflammatory gene expression pattern (Y. S. 
Lee et al., 2014). However, no evidence of increase in hypoxia in adipose tissue from 
obese human subjects was found as measured by net adipose tissue oxygen consumption 
(Goossens et al., 2011; Hodson, Humphreys, Karpe, & Frayn, 2013). A plausible 
explanation for this discrepancy is depot specific effect. The studies involved in human 
subjects were restricted to subcutaneous adipose tissue. Since abdominal fat is more 
relevant to obesity-induced inflammation, it is possible that visceral adipose tissue in 
obese human subjects have hypoxic condition. Although there are conflicting results 
regarding adipose tissue hypoxia during the onset of obesity, together these reports reveal 
the existence of potential local hypoxic region in hypertrophied visceral adipocytes, 
which may ultimately results in inflammation and ATM recruitment.  
Adipose tissue is not just a storage depot, but also an endocrine organ, which 
secretes a large number of molecules implicated in regulating the metabolic function of 
other tissues. (Kershaw & Flier, 2004). Examples of adipose tissue derived factors 
include leptin, adiponectin, TNF-α, IL-6 and MCP-1 (Kershaw & Flier, 2004; H. Xu et 
al., 2003). As a part of pathophysiological mechanisms of obesity, hypertrophied 




response of monocytes (Sun et al., 2011). Sartipy and Loskutoff demonstrated that 
obesity induces expression of MCP-1 in white adipose tissue (Sartipy & Loskutoff, 
2003). Additionally, Weisberg et al. demonstrated that the C-C motif chemokine 
receptor-2 (CCR2), a receptor for MCP-1 (also known as CCL2), modulates monocytes 
and macrophage recruitment in obese adipose tissue (Weisberg et al., 2006). When CCR2 
deficient mice (CCR2 KO) was fed with a high-fat diet, both ATM-related gene 
expressions and ATM content were reduced with improved systemic insulin resistance 
(Weisberg et al., 2006). The latter study also identified a potential ATM chemoattractant 
molecule by deleting CXC motif chemoattractant ligand-14 (CXCL14) in mice (Nara et 
al., 2007). Upon a high-fat feeding CXCL14 KO mice showed decreased in ATM content 
regardless of improved insulin resistance as compare to control mice (Nara et al., 2007). 
Together, these results suggest that CCR2 ligands, such as MCP-1, CXCL14 and possibly 
many other chemotactic ligands, are the critical factors that cause ATM accumulation.  
As adipocyte volume expands, adipose tissue basal lipolysis also increases 
(Duncan, Ahmadian, Jaworski, Sarkadi-Nagy, & Sul, 2007). If adipocyte hypertrophy 
continues it eventually results in excess local and systemic free-fatty acids (FFAs) during 
the development of obesity. FFA, the lipid product of triglyceride hydrolysis, can 
stimulate inflammation by binding and activating toll-like receptor-4 (TLR4) (Cullberg, 
Larsen, Pedersen, & Richelsen, 2014; Shi et al., 2006). In vivo adipose tissue from TLR4 
deficient compared to wild-type mice expresses less TNF-α, IL-6, MCP-1 after 8 hours of 
intravenous lipid infusion. Systemically, Tlr4-deficient mice has reduced insulin 
resistance following intravenous lipid infusion and after a high saturated fat diet feeding 




activate myeloid cells to induce pro-inflammatory expressions via TLR4 or TLR2 (M. T. 
Nguyen et al., 2007). In addition, FFAs instigate ER stress pathway both in vitro and in 
vivo, which eventually induces inflammation (Jiao et al., 2011; Pierre et al., 2013). These 
data indicate that FFA acts as a ligand of TLR4 to promote inflammation and ultimately 
induce ATM recruitment in hypertrophied adipose tissue.  
  Kosteli et al. directly tested the role of lipolysis in ATM recruitment by 
physiologic, pharmacologic, and genetic manipulations in mice (Kosteli et al., 2010). 
They found that during weight loss ATM content increased, peaking at the time lipolysis 
was highest. Furthermore, pharmacologically inducing or genetically inhibiting lipolysis 
increased and reduced adipose tissue FFA release and macrophage content in tandem , 
suggesting that FFA concentration is a direct regulator for ATM recruitment (Kosteli et 
al., 2010). Taken together, these data suggest that dysregulation of FFA flux in obesity 
both indirectly recruits ATMs by inducing inflammation in adipocytes and directly 
induces ATMs to uptake the excess lipids in adipose tissue.  
  During the development of obesity, macrophages infiltrate into adipose tissue. 
The ATM infiltration demonstrates a tight link between metabolic stress and innate 
immunity. However, specific molecular mechanism of ATM recruitment is not fully 
understood, yet. The proposed factors and mechanisms of ATM recruitment are the 
results of dynamic tissue remodeling processes. The aforementioned current findings 
suggest that dead adipocytes, adipocyte-derived chemokines, hypoxia, and excess FFA 
are all important features that induce ATM recruitment. Taken together, ATM 
accumulation in obesity is induced by not only one leading aspects, but rather caused by 




1.3 Other Immune Cells in Adipose Tissue in Obesity 
        After the discovery of the link between immunity and metabolism, many studies  
prompted to delineate the potential function of other immune cells in adipose tissue. 
Although ATM recruitment largely contributes to obesity-induced insulin resistance, 
several studies revealed the role of other immune cells in adipose tissue. In addition to 
macrophages, other innate and adaptive immune cells are found in adipose tissue and 
have been implicated in the both obesity-associated inflammation and insulin resistance 
(Mathis, 2013). 
        ATMs are the largest immune cell population in adipose tissue in obesity. The other 
innate immune cell populations found in adipose tissue and altered by adiposity include 
mast cells, eosinophils, neutrophils, dendritic cells and natural killer cells (NK cells). Liu 
et al. identified a potential role for mast cells in obesity-induced insulin resistance by 
genetically modulating Kit, a growth factor receptor essential for mast cell differentiation 
and survival in mice, and by pharmacologically inhibiting mast cell activity (J. Liu et al., 
2009). In the context of a western diet, both genetically mutated and pharmacological 
stabilization of mast cells reduced body weight gain, decreased levels of inflammatory 
cytokines and improved glucose homeostasis, suggesting that mast cells contribute to 
obesity-induced inflammation and systemic glucose homeostasis (J. Liu et al., 2009). 
Talukdar et al. discovered that neutrophils and their secreted elastase also contribute to 
obesity-induced inflammation and insulin resistance (Talukdar et al., 2012). Genetic and 
pharmacological manipulations that reduce neutrophil-derived elastase function in mice 
markedly lower the number of adipose tissue neutrophils, which was accompanied by 




Upon a high fat feeding, lower expression of inflammatory markers in both adipose tissue 
and liver were observed, with improved insulin sensitivity in mice in which the 
neutrophil elastase (Elane) was genetically deleted, indicating that neutrophils are 
additional immune cells that also contribute to metabolic inflammation and insulin 
resistance (Talukdar et al., 2012). 
           In contrast eosinophils have been found to have a beneficial effect on adipose 
tissue inflammation and systemic metabolism. Eosinophils are a primary source of the 
Th2 cytokine IL-4. Il-4 induces differentiation of alternatively activated phenotype in 
macrophages (Wu et al., 2011). Eosinophil-deficient mice (mutation in Gata1 promotor) 
increased adipose tissue mass with impaired glucose homeostasis whereas 
hypereosinophilic IL-5 transgenic mice (IL-5tg) decreased weight of adipose tissue with 
enhanced insulin sensitivity (Wu et al., 2011). Together, these results argue that all innate 
immune cells identified in adipose tissue contribute to the inflammatory state of adipose 
tissue and modulate systemic metabolism.  
         Adaptive immune cell populations including T cells, T-regulatory cells (Tregs) and 
B cells also exert critical effects on adipose chronic inflammation, ATM recruitment and 
systemic metabolism. Nishimura et al. defined the function of CD8+ effector T cells, also 
known as cytotoxic T cells, in dietary- and genetically-induced obese animals (Nishimura 
et al., 2009). They initially demonstrated that CD8+ T cell infiltration precedes ATM 
recruitment, where as the number of both CD4+ T cell and Tregs diminishes during a 
high fat feeding (Nishimura et al., 2009). More importantly, the group showed that 
antibody-induced depletion of CD8+ T cells and genetic deficiency of CD8+ T cells 




transcriptional profiles in obese adipose tissue, which was accompanied by reduced 
insulin resistance (Nishimura et al., 2009). This implied that CD8+ T cells initiated the 
immune response to obesity.  
             As briefly mentioned above, Tregs were shown to have inverse relationship with 
obesity and inflammation. Tregs suppress inflammatory and immune functions of many 
cells.  Deficiency in Tregs leads to autoimmune disorders in both rodents and humans 
(Josefowicz, Lu, & Rudensky, 2012). Feuerer et al. examined in Tregs in adipose tissue 
of ob/ob, Ay/a, and dietary-induced obese as compare to WT counterparts (Feuerer et al., 
2009). In lean animals Tregs are unusually numerous in epididymal adipose tissue 
comprising ~50% of CD4+ T cells compared to ~20%, for example, present in spleen.  
More strikingly, obesity reduced number of Tregs in epididymal adipose tissue of mice 
(Feuerer et al., 2009). Genetic and pharmacologic manipulations that increase Tregs in fat 
reduced obesity associated adipose tissue inflammation and insulin resistance, while 
depletion of Treg exacerbated these phenotypes (Feuerer et al., 2009).  
         Another component of adaptive immunity, humoral immunity, is mediated by B 
cells. Winer et al. investigated the role of B cells in obesity-induced inflammation also 
through the genetic and pharmacologic means (Winer et al., 2011). The group found that 
accumulation of B cells during a high-fat feeding along with T cells and ATMs and 
induction of IgG antibody concentration in both serum and visceral adipose tissue lysates. 
Genetic ablation of immunoglobulin mu-heavy chain knockout mice (Bnull) with a high-
fat feeding enhanced glucose homeostasis with reduced number of M1 macrophages and  
stromavascular cell (SVCs)-derived IFN-γ and TNF concentrations. Consistently, 




improved systemic glucose tolerance with decreased local production of IFN- γ and TNF 
from SVCs (Winer et al., 2011). In addition, adoptive transfer of high fat fed WT B cells 
to high fat fed Bnull mice aggravated insulin resistance and induced the IFN-γ and TNF-α 
level in serum (Winer et al., 2011). Subsequently, to examine the potential role of IgG in 
glucose homeostasis, Winer and colleagues purified IgG from mice fed with normal 
chow diet or high fat diet and transferred to Bnull mice (Winer et al., 2011). They 
observed glucose intolerance in Bnull mice treated with IgG from high fat fed mice as 
compare to Bnull mice or Bnull mice injected with IgG from mice fed with normal chow 
diet (Winer et al., 2011). Thus, the study suggests that the infiltrated B cells locally 
produce pathogenic IgG in adipose tissue, which contributes to obesity-induced systemic 
insulin resistance (Winer et al., 2011). 
          Over the last decade research has revealed that changes in metabolic state activate 
both the innate and adaptive arms of the immune system and that together many cells 
play important roles in obesity-induced adipose tissue inflammation and contribute to 
systemic insulin resistance. Most of the studies, however, have focused almost 
exclusively on the inflammatory actions of immune cells in adipose tissue. Since little is 
known about the non-inflammatory manner in which immune cells and adipocytes 
interact, further studies needs to be done in the future. 
 
1.4 The Role of Adipose Tissue Macrophages and Phenotype 
The correlation of ATM content with impairment of insulin action, lead to a large 
number of studies to identify  the functions and secreted factors of ATMs that contribute 




catabolic factors, which inhibit canonical insulin signal in adipose tissue (Lumeng & 
Saltiel, 2011). However, considering the important developmental function of tissue-
specific macrophages (Pollard, 2009), the non-inflammatory role of ATMs should be 
further investigated.  
         Even though lean adipose tissue has fewer macrophages compare to adipose tissue 
from obese individuals, ATMs are present in lean animals. Lumeng et al. introduced the 
notion of M1/M2 dichotomy by comparing lean and obese ATM phenotype. They 
described that ATMs from lean mice express the pan-macrophage protein F4/80+ but not 
the integrin Cd11c. In contrast ATMs from obese mice express both F4/80 and Cd11c 
(Lumeng, Bodzin, & Saltiel, 2007). They argued that  F4/80+Cd11c-  are alternatively 
activated ATMs (M2) and express anti-inflammatory molecules including Il-10, Chi313, 
Arg1, Mrc1, Mgl1, and Mgl2 whereas F4/80+Cd11c+ ATMs abundant in adipose tissue 
of obese mice, they argued are classically activated (M1), and express pro-inflammatory 
transcripts including Tnf, IL-6 and Nos2 (Lumeng et al., 2007). Based on these 
observations the authors suggested that classically activated-M1 ATMs were largely 
responsible for both the inflammatory profile of adipose tissue and obesity-induced 
insulin resistance. To test this hypothesis Patsouris and colleagues acutely depleted 
CD11c+ cells, including CD11c+ ATMs using a mouse that expressed a transgenic 
construct of diphtheria toxin receptor under the Cd11c promoter (Patsouris et al., 2008). 
After the depletion of Cd11c+ cells, obese mice showed improved glucose homeostasis 
and reduced inflammation, suggesting the association of Cd11c+ expressing ATMs and 




           However, emerging evidence suggests that M1/M2 “phenotypic switch” model is 
an oversimplified description of the complex phenotypes and roles of ATMs in obesity. 
Shaul et al. found that Cd11c+ ATMs expressed a mixed M1 and M2 transcriptional 
profile with some of M1 genes up-regulated and others down-regulated by obesity.  
Similarly, M2-related tissue remodeling gene expressions were also found in the Cd11c+ 
ATMs (Shaul, Bennett, Strissel, Greenberg, & Obin, 2010). Additionally, Fischer-
Posovszy et al. observed up-regulated M2 macrophage markers, Cd301 and Cd206, in 
CD11c+ ATMs from the aforementioned FAT-ATTAC mice (Fischer-Posovszky, Wang, 
Asterholm, Rutkowski, & Scherer, 2011). In a  recent detailed analysis of CD11c+ and 
CD11c- ATMs, Xu et al. found no significant distinct M1/M2 transcriptional profile 
associated with either Cd11c- or Cd11c+ ATMs (X. Xu et al., 2013). Furthermore, 
obesity did not activate the classical transcriptional profile in Cd11c+ ATMs rather the 
authors found that obesity activates a complex lysosomal-dependent lipid catabolic 
program in Cd11c+ ATMs (X. Xu et al., 2013).  
          Therefore, although it is now clear that ATMs contribute to chronic-low grade 
inflammation in adipose tissue, their phenotype of M2 to M1 polarization during the 
onset of obesity seems inaccurate. Since the macrophage infiltration is one of the 
homeostatic responses to “spill-over” of lipid from the storing organ, the function of 
ATM can be closely related to metabolize the overloads of lipids and also to remodel the 
overwhelmed adipose tissue (Fischer-Posovszky et al., 2011; Kosteli et al., 2010; X. Xu 
et al., 2013). Thus, the future investigations should be focused on further elucidating the 





1.5 Trophic Actions of Macrophages  
In addition to their roles as mediators of the innate immune response and in 
clearance of foreign pathogens, macrophages have tissue specific functions that are 
important in development and maintenance of homeostasis. These trophic functions are 
relatively poorly understood but vary widely depending upon the tissue of residences of 
each macrophage population (Pollard, 2009). For example, in bone osteoclasts – 
multinucleated macrophages – work in balance with osteoblasts to maintain healthy bone.  
Osteoblasts lay bone mineralized tissue while osteoclasts resorb bone. If the function of 
osteoclasts is impaired bone becomes too dense and lacks flexibility. If osteoclasts are 
over active compared to osteoblasts osteopetrosis results. In addition, osteoclasts produce 
trophic factors important to maintain osteoblast function. Thus, despite the fact that 
osteoclasts produce classic inflammatory molecules including TNF and IL6, their 
primary function is critical for bone health and largely independent of any inflammatory 
action.  
The non-inflammatory functions of ATMs are largely unknown. Recent studies 
from our laboratory suggest that similar to osteoclasts, which serve an important in the 
turnover of bone, ATMs serve a role in the turnover of triglycerides and lipids in adipose 
tissue. Depletion of macrophages from adipose tissue increases the release of free fatty 
acids from fat, while acute inhibition of lysosomal function reduces lipolysis (X. Xu et 
al., 2013). These findings suggest that macrophages take up and metabolize lipids in a 
manner important for its release from fat. However, the ability of ATMs to release factors 




while the production of many inflammatory cytokines that are inherently catabolic, 
including TNF, has been studied, the production of anabolic factors by ATMs has not.  
  
 1.6 Insulin-like Growth Factors. 
       In metazoans, insulin and its related proteins are dominant anabolic factors. In 
mammals, in addition to insulin there are two homologous proteins that play critical roles 
in development, insulin-like factor 1 and 2 (IGF1, IGFII). IGF1 is the well characterized 
member of the IGF family and its regulation is complex (Le Roith, Bondy, Yakar, Liu, & 
Butler, 2001). Whereas insulin is produced exclusively by beta-cells of the pancreas in 
response to glucose and other nutrients, the expression of IGF1 is regulated both by the 
systemic release of growth hormone (GH), and local factors within tissues. In addition, 
IGF binding proteins (IGFBP-1 through -6) modulate the availability of IGF1. Finally, 
not only is IGF1 homologous to insulin, its high affinity receptor IGF1R is homologous 
to the insulin receptor.   
        Igf1 mRNA expression in liver is 10- to 100-fold greater than majority of other 
organs, except adipose tissue (Butler & LeRoith, 2001). So, to examine the role of liver-
derived IGF1, two independent groups generated hepatocyte-specific IGF1 KO mice 
using the Cre-LoxP system (Sjogren et al., 1999; Yakar et al., 1999). Although they used 
different Cre to target liver-specific IGF- deletion in mice, the result was nearly identical. 
Surprisingly, they discovered no significant growth retardation even with ~75% reduction 
in serum IGF1, indicating hepatocyte-derived IGF1 largely contributes to circulating 
IGF1 but is not required for normal development (Sjogren et al., 1999; Yakar et al., 




hepatic IGF1 secretion and a negative feed forward loop exists in GH-IGF1 axis 
(Berelowitz et al., 1981; Le Roith et al., 2001). Genetic ablation of IGF1 in liver also 
revealed the increased growth hormone (GH) level in serum, confirming the negative 
feedback system between GH and IGF1 (Sjogren et al., 1999). GH not only regulates Igf1 
expression from liver, but also stimulates Igf1 expression in other tissues (Lowe, Lasky, 
LeRoith, & Roberts, 1988; Lowe, Roberts, Lasky, & LeRoith, 1987). Injection of GH to 
hypophysectomized rat induced Igf1 mRNA expression lung, kidney, skeletal muscle, 
heart and liver (Lowe et al., 1988; Lowe et al., 1987). Thus, these studies suggest that GH 
directly regulates IGF1 production in liver and extra-hepatic tissues.  
         The durability of circulating IGF1 is regulated by IGFBPs. The six IGFBPs are all 
structurally homologous and specifically bind to IGFI and IGFII, but negligibly bind to 
insulin (J. I. Jones & Clemmons, 1995). The biological action of IGFBPs are proposed as; 
to carry IGFs in plasma to other tissues, to inhibit clearance of IGF1 in serum, and to 
modulate interaction of IGFs and their receptors so that they indirectly regulate IGFs 
action in cells (J. I. Jones & Clemmons, 1995). Of the six IGFBPs, IGFBP-3 has been 
shown to mostly interact with IGF1 and acid labile subunit (ALS) to form a ternary 
complex of IGF-IGFBP-ALS. Almost 75% of IGF1 is bound in this ternary form and do 
not readily mobilize from vascular compartment, which has half-life of 12- to 15-hours. 
In contrast, free IGF1 in circulation only has half-life of less than 10 minutes (J. I. Jones 
& Clemmons, 1995). The bioavailability of IGFBPs is controlled by post-translational 
modification such as phosphorylation or glycosylation and by specific proteases of each 
IGFBP (J. I. Jones & Clemmons, 1995). Also, it has been hypothesized that IGFBPs have 




function (J. I. Jones & Clemmons, 1995; Le Roith et al., 2001). Nevertheless, it seems 
clear that IGFBP-3 is necessary to stabilize IGF-1 half-life in blood and to distinguish 
bound form of IGF1 from free IGF1. 
             IGF-1 transcripts comprises of several different isoforms. Though IGF1 
transcript is alternatively spliced, the all isoform transcripts give rise to the same mature 
70-amino acid peptide of IGF1 (Oberbauer, 2013). The IGF1 pre-pro-peptides are 
comprised with leader, signal sequence, and carboxy-terminus (Oberbauer, 2013). The 
leader sequences are determined by either exon 1 or exon 2 that will determine class 
1Ea/b or class 2 Ea/b transcripts (Wynes & Riches, 2005). The splicing of exon 1 and 2 is 
mutually exclusive and that creates different 5’ UTRs (Oberbauer, 2013). The signal 
sequences are exon 3 and 4, which encodes B, C, D, and A domain of mature peptide; 
exon 4 gives rise to nearly all mature peptides (Figure 1). The E-peptide includes 16-
amino acids from exon 4 following exon 5 and/or exon 6 (Figure 1). Though the function 
of E-peptide is unclear, exclusion or inclusion of exon 5 results in different stop codons, 
polyadenylation sites and 3’ UTRs (Oberbauer, 2013). Although the distinct biological 
roles of class 1 and class 2 transcripts are controversial and yet to be specified, it has been 
long hypothesized that class 1, the long form, is preferentially involved in 
paracrine/autocrine function while class 2, the short form, is more relevant to endocrine 
function (Oberbauer, 2013). Therefore, distinctive local versus systemic function of IGF1 
is perhaps determined in post-transcriptional level.   
        In earlier study, Rom et al. demonstrated that human activated alveolar macrophages 
produce IGF1 molecule and express Igf1 mRNA transcript (Rom et al., 1988). Moreover, 




selective ablation of proliferating microglia aggravates ischemic injury in the brain 
(Lalancette-Hebert, Gowing, Simard, Weng, & Kriz, 2007), suggesting that the microglia 
release IGF1 as a neuro-trophic factor in the context of the acute injury. Another recent 
study also indicates that the macrophages produce IGF1 molecule, which contributes to 
beneficial wound healing process. Lu et al. found that newly recruited macrophages via 
CCR2 in skeletal muscle express IGF1 both in mRNA and protein level under acute 
injury (Lu et al., 2011). They used CCR2 KO mice as the recruited macrophage 
deficiency model in skeletal muscle injury and discovered that skeletal muscle size and 
volume were significantly smaller in CCR2 KO than in WT mice (Lu et al., 2011). When 
recombinant IGF-1 was locally given to the CCR2 KO mice, the injured skeletal muscle 
size and volume were recovered at level comparable to the skeletal muscle of WT mice, 
indicating that the activated macrophage-derived IGF1 regulates acute injury in skeletal 
muscle (Lu et al., 2011). Furthermore, Bio GPS Novartis gene expression database 
showed that bone marrow derived macrophages express Igf1 at similar level to liver, 
suggesting that macrophages are the major extra-hepatic source of IGF1 (Gow, Sester, & 
Hume, 2010). Taken together, these findings illustrate that the macrophages are innate 
immune homeostatic modulator both in physiological and pathological setting and the 
potential function of tissue-specific macrophage derived-IGF1 exerts through local 
paracrine and autocrine fashion. 
           Our recent microarray transcriptional profile analysis also shows the abundant 
ATM expression of Igf1 in Cd11c- and Cd11c+ populations of both lean and obese 
adipose tissue, suggesting the potential role of ATM-derived IGF1 in obesity. Although 




Singer et al. showed that ATM-derived Neuropeptide Y (NPY), an anti-lipolytic factor 
and a pro-angiogenic factor, regulates obesity-induced inflammation in paracrine or 
autocrine way. Our microarray data and this recent report suggest that ATM-derived 
factors are not limited to catabolic factors but also include the factors that are beneficial 
to adipose tissue during the development of obesity. 
          Many of in vitro studies revealed that IGF1 action is important in cell cycle 
progression, cell proliferation, cell differentiation, inhibition of cell death and other 
cellular functions including immune cell modulation (J. I. Jones & Clemmons, 1995; Le 
Roith et al., 2001; Smith, 2010). In most cell lines, IGF1 exerts effect as anabolic factor 
inducing protein and carbohydrate synthesis as well as glucose uptake (J. I. Jones & 
Clemmons, 1995). Moreover, a number of genetic ablation in vivo studies demonstrated 
the essential function of IGF1in intrauterine and postnatal growth (Baker, Liu, Robertson, 
& Efstratiadis, 1993) and proved that IGF1 almost exclusively signals through its own 
cognate receptor, IGF1R (Butler & LeRoith, 2001; Nakae, Kido, & Accili, 2001). IGF1, 
however, can also signal through insulin receptor (IR) even though their binding affinity 
is approximately 100-fold less than its cognate receptor (Entingh-Pearsall & Kahn, 2004). 
IR and IGF1R are highly homologous tyrosine kinase receptors that share downstream 
signaling pathways (Entingh-Pearsall & Kahn, 2004; J. I. Jones & Clemmons, 1995). IR 
and IGF1R also can form a hybrid receptor although their exact function still need to be 
elucidated (Nakae et al., 2001). Similarly, though insulin’s binding affinity is higher to its 
own receptor, insulin can also bind to IGF-1R and exert metabolic signaling (Entingh-
Pearsall & Kahn, 2004). Boucher et al. further illustrated that insulin and IGF1 receptors 




however, each cognate ligand-receptor binding induces greater amplitude of gene 
expression (Boucher, Tseng, & Kahn, 2010). 
          Overall, the function and the regulation of IGF1 are rather complicated interacting 
with other IGF family of ligands, receptors, and binding proteins. Previous studies 
showed that IGF1 and insulin can alternatively bind to each other’s receptors and can 
mediate both mitogenic and metabolic signal transductions. Moreover, because the 
dramatic reduction of circulating IGF1 in liver-specific IGF1 KO did not lead to severe 
postnatal growth defect in mice, the investigation of questioning the role of local IGF1 is 
necessary to further understand the complex regulation and the function of IGF1 in 

















Rodent IGF1 Gene Structure 
 
Figure 1. The IGF1 gene structure  
Splicing and exons in the rodent gene generate distinct transcripts that vary in the 5′ and 
3′ ends though the mature peptide is invariant. Transcription initiation sites are denoted 
by solid arrows above the exons: sites designated 1–4 are ∼382, 343, 245, and 40 bases 
upstream of the 3′ end of exon 1, respectively and the two sites in exon 2 ∼70 and 50 
bases upstream of the 3′ end of exon 2. Sites preferentially used are indicated with 
asterisks. Translation initiation is denoted with open arrows below the exons. 










Oberbauer IGF-1 gene transcription
FIGURE 1 |The IGF-1 gene structure. Splicing and exons in the rodent
gene generate distinct transcripts that vary in the 50 and 30 ends though the
mature peptide is invariant (A). Transcription initiation sites are denoted by
solid arrows above the exons: sites designated 1–4 are s382, 343, 245,
and 40 bases upstream of the 30 end of exon 1, respectively and the two
sites in exon 2 s70 and 50 bases upstream of the 30 end of exon 2. Sites
preferentially used are indicated with asterisks. Translation initiation is
denoted with open arrows below the exons. The human IGF-I transcripts are
depicted in (B).
inclusion/exclusion of exons 5 and 6. The E domain function
remains unclear (Matheny et al., 2010) although much specula-
tion surrounds this domain as it introduces the greatest variability
into the IGF transcripts and has challenged consistent nomen-
clature. Inclusion or exclusion of exon 5 into the pre-pro IGF-I
polypeptide gives rise to transcripts differing in E-peptide forms,
termination codons, polyadenylation sites, and 30UTR’s (Shimatsu
and Rotwein, 1987; Shavlakadze et al., 2005).
SPLICING
In the rat, exclusion of exon 5 (that is, splicing exon 4 to exon 6)
creates the Ea peptide of 35 amino acids in length. Inclusion of
exon 5 (that is, splicing exon 4 to 5 and then 5 to 6) introduces 52
bases and a frame shift to generate an earlier stop codon in exon 6
thereby creating the Eb peptide of 41 amino acids; both Ea and Eb
have a common 30UTR (Shimatsu and Rotwein, 1987). In rats, the
Eb transcripts account for s10% of IGF-I transcript expression.
In contrast, the human Eb peptide is composed of only exons 4
and 5 (Rotwein et al., 1986) whereas the splice variant containing
exons 4, 5, and 6 is called the Ec peptide and is also referred to
as mechanogrowth factor (MGF) (Yang et al., 1996). The human
Eb splice variant is rarely detected in other species and then most
notably in mice with the murine exon 3, 4, 5 splice variant exist-
ing only for class 2 IGF-I isoforms (Shavlakadze et al., 2005). The
human Eb may reflect a poorly conserved 50donor splice site in
the human IGF-1 gene causing the spliceosome to exclude exon
6 (Shavlakadze et al., 2005). The human exon 5 has a nucleolus
localization sequence (Weber et al., 2000) and a polyadenylation
site (Chew et al., 1995). In rodents, the Ea peptide, but not the Eb,
contains two potential N -glycosylation sites (Roberts et al., 1987)
though their role in processing and function of the IGF-I peptide
remains unknown to date. Human IGF-IEa peptides possess only
a single glycosylation site (Duguay et al., 1995).
An additional regulatory feature is the existence of a purine rich
splicing enhancer site downstream of exon 5 that is recognized
by the serine-arginine protein splicing factor-2/alternate splicing
factor. Occupancy of this enhancer facilitates recruitment to the
spliceosome and increases the efficiency of inclusion of exon 5 into
the transcript. Importantly, the serine-arginine protein splicing
factor-2/alternate splicing factor is activated by phosphorylation
or by cellular localization which may mediate tissue and hor-
monal specific splicing of the IGF-1 transcript (Smith et al., 2002)
consistent with the more limited expression of the Eb forms.
PROMOTER
While there exist no classical transcription start site elements for
IGF-1, the 50UTR is highly conserved across human, rat, mouse,
sheep, and cattle genomes with basal promoter activity for exon 1
in the first 412 bp of the 50 flanking region, and negative regulatory
elements beyond that (Lowe and Teasdale, 1992). In the rat exon
1 has 4 transcript start sites: s382 (site 1), s343 (site 2), s245
(site 3), and s40 bp (site 4) upstream of the 30 end of exon 1 with
sites 2 and 3 used most frequently (Adamo et al., 1991a; Simmons
et al., 1993; Yang et al., 1995; Wang et al., 1997). Two additional
minor start sites are found at s361 and s353 bp upstream of the
30 end of exon 1 (Simmons et al., 1993). Usage of the four tran-
scription sites in exon 1 generate transcripts differing in signal
peptide structure. Sites 2 and 3 are upstream of a translation ini-
tiation codon and usage of either generates a 48 amino acid signal
sequence (Simmons et al., 1993; Yang et al., 1995) whereas usage
of site 3 is downstream of the translation initiation codon and the
signal sequence derived from this site is within exon 3 and is 22
amino acids long (Yang et al., 1995). An additional exon 1 trans-
lation initiation site exists in the human gene creating a 25 amino
acid signal sequence (Jansen et al., 1983).
Within the promoter region for exon 1, there exist DNAse I
hypersensitive sites (Thomas et al., 1995) that were uninfluenced
by GH suggesting complex transcriptional regulation of the gene.
Also described in the region were consensus sequences for hepa-
tocyte nuclear factor (HNF) transcription factor binding (Nolten
et al., 1996), CCAAT/enhancer binding proteins (C/EBP) (Nolten
et al., 1994), and GATA-binding protein motifs (Wang et al., 2000)
all perhaps involved in basal regulation of transcription. Other
enhancer elements within the promoter of exon 1 include an E




1.7 IGF1 and Insulin Signaling in Adipose Tissue 
	  	  	  	  	  	  	  	  	  	  	  Since the deletion of liver-specific IGF1 had no effect on postnatal growth, it raises 
question of crucial source and the function of local IGF1 in other tissues. Yakar et al. also 
demonstrated that adipose tissue has higher Igf1 mRNA expression as compare to other 
organs’ Igf1 expression, implying that fat can be another important source of IGF1 
(Yakar et al., 1999). Additionally, abovementioned Bio GPS Novartis gene expression 
data showed that adipose tissue is another organ that expresses abundant Igf1. Thus, IGF1 
and insulin action in fat should be closely viewed to delineate the specific local sources 
and the role of IGF1.   
         In the past, an in vitro study demonstrated that IGF1 is more potent than insulin to 
stimulate differentiation and lipogenesis in human bone marrow mesenchymal stem cells 
to mature adipocytes, denoting the critical action of IGF1 and its signaling in adipocyte 
differentiation (Scavo, Karas, Murray, & Leroith, 2004). In addition, several in vivo 
studies have prompted to explain the IGF1 and insulin signaling in adipose tissue. Bluher 
and the colleagues generated fat-specific insulin receptor knockout (FIRKO) mice and 
found significant reduction in body weight fat pad mass as compare to the WT mice 
(Bluher et al., 2002). The FIRKO mice also had phenotype of heterogeneous adipocyte 
size, suggesting the importance of insulin signal in adipose tissue development (Bluher et 
al., 2002). Correspondingly, brown adipose tissue-specific insulin receptor knockout 
(BIRKO) mice showed reduced interscapular brown adipose tissue weight with marked 
reduction of cell and fat droplet size as compare to their WT counterparts (Guerra et al., 
2001). In contrast, adipose-specific IGF1R knockout (IGF1RKO) mice have increased 




& Kopchick, 2009; Kloting et al., 2008). This study also showed higher adipose tissue 
Igf1 mRNA expression in adipose tissue with induction of serum IGF1 level in 
IGF1RKO as compare to WT mice, indicating the autocrine action of IGF1 in fat 
regulates systemic development (Kloting et al., 2008). Furthermore, a recent study of IR 
and IGF1R double knockout (FIGIRKO) mice demonstrated the severe lipodystrophic 
phenotype of white and brown adipose tissue in both a standard chow-diet fed and a high-
fat diet fed mice (Boucher et al., 2012).  
     Although the above mentioned mouse models were described as adipocyte-specific 
genetic deletion of IR and IGF1R, both studies used mice that have Cre under the fatty 
acid-binding protein-4, ap2, promoter (ap2-Cre). Recently, the growing number of 
evidences shows that ap2-Cre line is not very specific to adipocytes but leaks to target 
brain as well. Therefore, more cautious interpretation is required and more specific 
targeted deletion using Cre under the adiponectin promoter should be used to delete the 
genes in adipocytes. There is one recent study that can overcome this current limitation. 
In the American Diabetes Association Conference 2014, Sakaguchi and Kahn presented a 
poster regarding new FIGIRKO mice created by using inducible adiponectin-Cre 
(American Diabetes Association Conference 2014 Poseter;194-LB). Upon the treatment 
with tamoxifen, the IR and IGF-1R lox bearing mice drastically lost fat mass within 3 
days with impaired glucose homeostasis (American Diabetes Association Conference 
2014 Poseter;194-LB), showing that with more accurate genetic target also leads to 
analogous results as shown in the previous literatures, which emphasizes the important 




          Even though the insulin and IGF1 signaling in fat have been extensively studied, 
the cellular source of local IGF1 in adipose tissue is yet to be defined. Adipose tissue is 
composed of numerous cells; adipocyte, pre-adipocytes, endothelial cells, macrophages, 
T cells, Tregs, B cells, and NK cells. Among these potential IGF1 cellular sources, 
quantitative and qualitative contribution to adipose Igf1 expression and the local function 
of IGF1 will be determined in my thesis work.  
 
1.8 Adipose Tissue Lipolysis  
            Adipose tissue lipolysis is the process by which triacylglycerides (TG) are 
hydrolyzed to release free fatty-acids (FFAs) and glycerol. FFAs and glycerol ultimately 
reach the circulation and provide fuel for other organs especially the liver and muscles 
(Ahmadian et al., 2011; Duncan et al., 2007; Nielsen, Jessen, Jorgensen, Moller, & Lund, 
2014). The hydrolysis of TG is mediated by several lipases; currently well-defined 
lipases are hormone-sensitive lipase (HSL/LIPE), adipose triglyceride lipase 
(ATGL/PNPLA2), and monoacylglyceride lipase (MGLL) (Ahmadian et al., 2011; 
Duncan et al., 2007; Nielsen et al., 2014; Osuga et al., 2000; Zechner, Kienesberger, 
Haemmerle, Zimmermann, & Lass, 2009; Zechner, Strauss, Haemmerle, Lass, & 
Zimmermann, 2005). Complete lipolysis of TG requires three sequential hydrolytic steps 
(Nielsen et al., 2014). As shown in the Figure 2, the initial step is primarily mediated by 
ATGL converting TG to diacylglyceride (DG). Then DG is cleaved by HSL to release 
monoglyceride (MG) and another FFA. As the last step, MGLL cleaves MG to liberate 
FFA and glycerol (Duncan et al., 2007). Although other triglyceride hydrolases, 




evidence suggests that ATGL, HSL and MGLL are the dominant lipases in adipocytes 
(Duncan et al., 2007). 
          Although HSL is an important lipase, HSL alone cannot induce efficient lipolysis 
in adipose tissue. Genetic ablation of HSL in mice showed that basal lipolysis was not 
severely impaired and retained 40% of triglyceride lipase activities in white adipose 
tissue (Osuga et al., 2000; S. P. Wang et al., 2001). These findings implied that other 
lipases besides HSL exist in adipose tissue. Subsequently, a novel adipose tissue lipase, 
PNPLA2 was discovered by three independent groups (Jenkins et al., 2004; Villena, Roy, 
Sarkadi-Nagy, Kim, & Sul, 2004; Zimmermann et al., 2004). Lack of PNPLA2 in mice 
resulted in significant increase of white adipose tissue and brown adipose tissue with 
defective lipolysis phenotype (Haemmerle et al., 2006). PNPLA2 deficiency also led to 
massive TG accumulation in cardiac muscle, which eventually contributed to cardiac 
dysfunction due to myocardial fibrosis (Haemmerle et al., 2006). Therefore, this loss of 
function study in mice clearly demonstrated the essential role of PNPLA2 in lipolysis 
independent of HSL. 
          To examine the role of PNPLA2 in fat tissue, Amadian and colleagues generated a 
transgenic mice overexpressing Pnpla2 in adipose tissue. Overexpression of Pnpla2 in 
mice resulted increase in lipolysis, decrease in adipocyte size and TG content (Ahmadian 
et al., 2009). Furthermore, fat-specific genetic deletion of PNPLA2 in mice showed 
significant induction of white adipose tissue and brown adipose tissue weight (Ahmadian 
et al., 2011). The fat-specific PNPLA2 KO mice also had lower adipose lipolysis rate 




together, these findings demonstrate the important function of PNPLA2 specifically in 
adipose tissue lipolysis, where it directly affects TG storage in fat.  
             
1.9 The Regulation of Adipose Tissue Lipolysis 
When an individual exercises or fasts, lipolysis is induced to liberate FFAs as 
substrates for the liver, muscle and other tissues. During these states, catecholamines bind 
to beta-adrenergic receptors on the plasma membrane of adipocytes and stimulate Gs 
subunit of G-protein coupled receptor (GPCR) (Duncan et al., 2007; Nielsen et al., 2014). 
Activation of Gs subunit leads to interaction of adenylyl cyclase (AC) and converts ATP 
to cAMP to activate PKA (Nielsen et al., 2014). At re-feeding state, lipolysis is 
attenuated by insulin secretion. Insulin has been shown to inhibit lipolysis both through 
cAMP-dependent and –independent mechanisms (Duncan et al., 2007; Nielsen et al., 
2014). Upon binding of insulin to IR, IR undergoes auto-phosphorylation and leads to 
phosphorylation of IRS1/2 (Nielsen et al., 2014). This will results in activation of 
phosphatidylinositol-3-kinase (PI3K), which converts phosphatidylinositol-4,5-
biphosphate (PIP2) to phosphatidylinositol-3,4,5-triphosphate (PIP3) (Nielsen et al., 
2014). Then PIP3 stimulates phosphoinositide-dependent kinase (PDK) activating Akt to 
induce phosphodiesterase 3B (PDE3B) to degrade cAMP and eventually inactivates PKA 
(Nielsen et al., 2014). Thus, catecholamine activates physiological lipolysis whereas 
insulin primarily inhibits lipolysis. During the induction or inhibition of adipose tissue 
lipolysis, various downstream proteins are modified to target activation or attenuation of 




          The molecular mechanism of lipolysis requires not only lipases, but also other 
regulatory proteins (Duncan et al., 2007; Zechner et al., 2009). Perilipin (PLIN1) is the 
protein that resides on the surface of lipid-droplet in mature adipocytes and acts as a 
negative regulator of lipolysis to limit the access of lipases to TG in the lipid droplet 
(Duncan et al., 2007; Nielsen et al., 2014). When lipolysis is induced, phosphorylation of 
PLIN1 by protein kinase A (PKA) facilitates CGI-58 dependent activation of ATGL 
(Cornaciu et al., 2011; Duncan et al., 2007; Osuga et al., 2000). Similarly, PLIN1 
phosphorylation enhances HSL activity and the second step in TG hydrolysis (Miyoshi et 
al., 2006). Another lipolysis regulatory protein has been proposed as G0S2 protein, which 
inhibits adipose lipolysis by direct protein-protein interaction of G0S2 and ATGL 
(Nielsen et al., 2014). In short, numerous accessory proteins are involved in lipolysis in 
which by directly or indirectly interacting with lipases and lipid-droplets. 
 
1.10 The Role of Lipolysis in Adipose Tissue Macrophage Recruitment 
   When non-esterified fatty-acids are released during induction of lipolysis, 
metabolically active organs uptake FFAs to use as substrates. However, in some 
pathologic states, the delivery of FFAs to tissues exceeds the energetic requirements and 
lipids accumulate. This is a characteristic of obesity and lipodystrophy. This 
accumulation of ectopic lipid leads to a state of lipotoxicity whereby lipid metabolites, 
primarily those of FFA, impairs insulin signaling. As a physiological and a 
pathophysiological response of increased lipolysis, recent finding illustrated that lipolysis 
promotes myeloid cell recruitment in adipose tissue (Kosteli et al., 2010). In this report, 




weight loss stage. Figure 3 describes the peak of adipose tissue lipolysis where early 
weight loss stage is when both basal and demand lipolysis rate are combined to be the 
highest. Kosteli et al. suggested that ATMs are recruited to buffer the excess FFA flux in 
adipose tissue (Kosteli et al., 2010). In support of this, Xu et al. described the primary 
function of Cd11c+ ATMs as lipid metabolizing immune cells through lysosomal 
activation in obesity, implying that ATMs are involved in clearing up the excess FFAs 
and metabolizing the lipid under increased lipolysis condition (X. Xu et al., 2013). 
      Though previous findings show that ATMs are the regulator of adipose tissue 
lipolysis, there are many questions still remain to be answered. How do ATMs uptake 
lipids? Do ATMs uptake lipids through lipase-dependent way and through lipid 
transporters? Or do they simply phagocytose extracellular lipid debris from dead 
adipocytes? Another important question is why do ATMs uptake FFAs and in which 
mechanism do they metabolize the lipids?  I will try to elucidate some of these 
unanswered questions in my work, if not all, by investigating ATM lipid content under 













Figure 2. Adipose Tissue Lipolysis Steps 
Complete lipolysis of TG requires three sequential hydrolytic steps. The initial step is 
primarily mediated by ATGL converting TG to diacylglyceride (DG). Then DG is 
cleaved by HSL to release monoglyceride (MG) and another FFA. As the last step, 
MGLL cleaves MG to liberate FFA and glycerol. 




provides the organism with an FFA-buffering system of
essentially unlimited capacity (Frayn 2002). However, the
metabolic consequences of an excessive expansion of AT
are considerable. In humans, obesity is closely associated
with numerous risk factors that constitute the so-called
metabolic syndrome. This includes abdominal obesity,
hypertension, dyslipidemia, and glucose intolerance,
which are key elements in the pathogenesis of cardiovas-
cular disease and type 2 diabetes (Alberti et al. 2009). The
physiological link between obesity and metabolic disease
in humans is currently not completely understood, and
one of the great enigmas is the remarkable individual
differences in the predisposition to obesity-induced
metabolic disease. This has led to the proposal of the –
AT expandability hypothesis – (Virtue & Vidal-Puig 2010,
Hardy et al. 2012), which states that the capacity of AT to
expand appropriately when lipid storage is needed is
limited for a given individual. Hence, when the limit is
exceeded, lipids begin to accumulate in ectopic tissues
causing metabolic dysfunction and insulin resistance due
to lipotoxic effects. An emerging view is that this
lipotoxicity is likely not caused by excess TG in itself,
but rather by an excess of lipid intermediates and
metabolites released from hypertrophic adipocytes.
Several recent reviews have addressed these mechanisms
in detail (Boura-Halfon & Zick 2009, Virtue & Vidal-Puig
2010, Copps & White 2012, Hardy et al. 2012, Zechner
et al. 2012, Czech et al. 2013). Notably, it is now clear that
besides serving as energy-dense metabolic substrates,
most, if not all, lipolytic products and intermediates like
diacylglycerol (DG), monoacylglycerol (MG), and FFA
(and metabolites derived from these) play essential roles
in multiple signaling pathways, both at the systemic and
at the intracellular level (Zechner et al. 2012). When
present in excess, several of these lipid intermediates have
been suggested to induce insulin resistance in ectopic
tissues by interfering with insulin signaling at the level of
the insulin receptor substrate (IRS) proteins (Boura-Halfon
& Zick 2009, Copps & White 2012).
Being the major lipid species released from AT, FFA is
likely one of the key elements in ectopic lipid accumu-
lation and lipotoxicity. Thus, experimental elevation of
plasma FFA levels in human subjects acutely and dose
dependently counteracts peripheral insulin-stimulated
glucose uptake and oxidation (Belfort et al. 2005, Gormsen
et al. 2007, Hoeg et al. 2011). Furthermore, high FFA levels
attenuate the insulin-mediated suppression of hepatic
glucose production contributing to the impairment of
whole-body glucose tolerance (Roden et al. 2000). Consist-
ently, improvements in whole-body insulin sensitivity
and oral glucose tolerance can be obtained by pharma-
cological reductions of chronically elevated plasma FFA
levels both in type 2 diabetic patients, obese nondiabetic
subjects, and nondiabetic subjects genetically predisposed
to type 2 diabetes (Santomauro et al. 1999, Cusi et al.
2007). Accordingly, excessive FFA mobilization from AT
is widely conceived as playing a pivotal role in insulin
resistance and type 2 diabetes, suggesting that dysregula-
tion of AT lipolysis in the obese state is a contributing
factor to the development of metabolic disease.
Major signaling pathways in AT lipolysis
Lipolysis is the sequential hydrolysis of one TG molecule
into three FFAs and one glycerol by a class of hydrolytic
enzymes commonly known as lipases. In mammalian
lipolysis, three lipases act in sequence with the concomi-
tant release of one FFA in each step (Fig. 1); adipose TG
lipase (ATGL) converts TG to DG and is the rate-limiting
enzyme in the lipolytic pathway (Zimmermann et al.
2004). DG is hydrolyzed to MG by hormone-sensitive
lipase (HSL; Haemmerle et al. 2002), and monoglyceride
lipase (MGL) cleaves MG into glycerol and FFA (Fredrikson
et al. 1986). The major positive regulators of human
lipolysis are catecholamines and natriuretic peptides
(NPs), while antilipolysis primarily is mediated by insulin
and catecholamines.
Catecholamines
The catecholamines, and specifically the stress hormones
adrenaline and noradrenaline, are the primary mediators
of adrenergic signaling in AT. The manner by which
catecholamines regulate lipolysis is unusual as these
hormones are able to both stimulate and inhibit lipolysis
depending on their relative affinity for different adrenergic
receptors (ARs). Thus, stimulation of lipolysis requires the
activation of b-ARs on the surface of the adipocyte, while
antilipolytic signals are transmitted by the a2-AR




Schematic illustration of the lipolytic pathway. To fully hydrolyze TGs,
ATGL, HSL, and MGL act in sequence, with the release of one FFA in each
step. This successively converts TG to DG, then toMG, and finally to glycerol
and a total of tree FFA. TG, triglyceride; ATGL, adipose TG lipase; DG,
diacylglycerol; FFA, free fatty acid; HSL, hormone-sensitive lipase; MG,
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Figure 3. Adipose Tissue Lipolysis During Weight Loss 
When an individual gains weight, basal lipolysis increases due to hypertrophied 
adipocytes. During the early weight loss stage, total adipose tissue lipolysis rate reaches a 
peak as demand lipolysis increases when basal lipolysis is still high. At the late weight 
loss stage, the lipolysis rate is attenuated as basal lipolysis decreases as compare to the 
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Chapter 2: Dynamic Regulation and Function of IGF1 in Adipose Tissue 
Introduction 
Genetic ablation studies of IGF1 and its cognate receptor IGF1R in mice have 
shown that IGF1 is a crucial factor for prenatal and postnatal development (J. P. Liu, 
Baker, Perkins, Robertson, & Efstratiadis, 1993). Although hepatic-derived IGF1 
constitutes more than 75% of circulating IGF1, mice lacking hepatocyte derived-IGF1 do 
not have any gross abnormalities, indicating that extra-hepatic, locally produced IGF1 
action may largely  be responsible for IGF1-dependent development (Sjogren et al., 1999; 
Yakar et al., 1999). Recent studies using cell/tissue-specific deletion of IGF1 illustrate 
the importance of local production on the maintenance of tissue homeostasis. Genetic 
ablation of brain macrophages and microglia by injecting ganciglovir in CD11b-
thymidine kinase mutant-30 mice significantly reduced macrophage IGF1 protein 
expression and exacerbated ischemic injury in brain (Lalancette-Hebert et al., 2007). In 
addition, impaired skeletal muscle repair was found along with reduction in IGF1 
production of skeletal muscle in CCR2 KO mice, showing that CCR2-dependent 
recruited macrophages secrete IGF1 to regulate acute skeletal muscle injury (Lu et al., 
2011). 
            Receptor deficient studies in mice have revealed a crucial role for insulin/IGF1 
signaling in the development and metabolic function of fat and given that reductions in 
circulating concentrations of IGF1 have no discernable effects on adipose tissue 
development and systemic metabolism, we hypothesized that local production of IGF1 
would be crucial. Furthermore, given that macrophages express Igf1 at levels comparable 




individuals, we hypothesized that any local IGF1 effects on adipose tissue development 
and metabolism, would be especially pronounced during the development of obesity. In 
our model ATMs are the significant source of IGF1 in obese adipose tissue. Lean adipose 
tissue, however, has few ATMs thereby likely contribute little to local IGF1. We predict 
that in lean animals, adipocytes, would be the major source of IGF1. If our hypotheses 
are correct deletion of IGF1 from adipocytes but not macrophages would have a large 
effect in lean animals but in obese animals deletion of macrophage-IGF1 would have 
measurable developmental (reduced mass) and metabolic (increased basal lipolysis) 
effects.  
   To test our hypotheses, we performed gene expression analyses of adipose tissue 
from lean and obese mice. We employed clodronate-encaptulated liposomes to deplete 
ATMs in adipose tissue and utilized fluorescence activated cell sorting (FACS) analysis 
to identify cellular source of IGF1 in adipose tissue. Lastly, we generated adipocyte- and 
myeloid cell-targeted IGF1 deleted mouse models using Cre-LoxP system and analyzed 
adipose tissue and metabolic parameters to determine the local function of IGF1 in 












Animal and Animal Care 
C57BL/6J lean male mice were obtained from Jackson Laboratory. C57BL/6J male mice 
were fed with a high-fat diet (60% kcal high fat, Research Diet, Inc) for indicated periods 
of time to obtain obese animals. C57BL/6J background homozygous male and female 
Lysozyme2-Cre (Lyz2-Cre) mice were obtained from Jackson Laboratory and 
homozygous male and female Igf1fl/fl mice were kindly provided by Derek LeRoith 
(Mount Sinai School of Medicine, NY). All mice were housed in ventilated Plexiglas 
cages within pathogen-free barrier facility maintained in a 12-hour light/12-hour dark 
cycle. All protocols were approved by the Columbia University International Animal 
Care and Use Committee. 
 
Generation of macrophage-specific IGF1 Knockout Mouse (Mac-IKO)  
We generated myeloid cell specific IGF1 knockout mice using Cre-LoxP method. We 
crossed C57BL/6J background Igf1 fl/fl mice with Lyz2-Cre mice. To assess 
recombination, we extracted genomic DNA from purified ATMs, as well as peritoneal 
macrophages, and did PCR specifically in the loxP region bearing exon 4 of Igf1. PCR 
product from Igf1 fl/fl genomic DNA size was 1000 base pairs, which indicates full 
length of floxed region. In contrast, genomic PCR size from Mac-IKO (both Igf1 
fl/fl;Lyz2-Cre+/- and Igf1 fl/fl;Lyz2-Cre+/+) was 200 base pairs, indicating the efficient 
recombination. Therefore, we observed specific and efficient deletion of exon 4 of Igf1 in 





Confirmation of targeted genetic deletion in Mac-IKO mice 
The genomic deletion was confirmed by genomic PCR in the region of loxP sites 
flanking exon 4 of the Igf1 gene. Genomic PCR primers were designed flanking region of 
exon 4. The forward primer was designed in region of intron 3 of the Igf1 gene (beyond 
BamHI restriction site) and the reverse primer was designed in region of intron 4 of the 
Igf1 gene (beyond EcoRI restriction site). Genomic PCR product size from mice carrying 
homozygous allele of loxP without Cre gene is 1kb whereas DNA product from mice 
carrying both allele of loxP and Cre gene is 200bp. DNA extraction from both peritoneal 
macrophages and ATMs were done for PCR to confirm specific and efficient 













Figure 1. Igf1 deletion in myeloid cells 
A)Primer design targeted for exon 4 region of Igf1 B)PCR product of exon 4 region of 
Igf1 from F4/80+ cells (ATMs) of perigonadal adipose tissue in lean mice (Lane 1 




Generation of adipocyte-specific IGF1 Knockout mice (Adipo-IKO) 
We generated adipocyte specific IGF1 knockout mice using Cre-LoxP method. We 
crossed C57BL/6J background Igf1 fl/fl mice with Adiponectin-Cre mice. To assess 
recombination, we extracted RNA from lean perigonadal adipose tissue and measured 
relative mRNA gene expression of Igf1. We observed ~80% reduction of Igf1 gene 
expression level as compare to control perigonadal adipose tissue Igf1 expression. 
 
Adipose Tissue Explant  
Perigonadal fat pad was surgically removed from lean and obese male mice. The 
removed tissue was cut into 1mm pieces (∼120 mg total weight) and were incubated in 
phenol-free DMEM (Invitrogen) containing 2% fatty acid–free BSA (Sigma-Aldrich) at 
37°C for initial 4 hours. After 4 hours of culture, the conditioned media were removed to 




experiment, each well of adipose tissue explant was treated with clodronate-encaptulated 
liposomes or adenovirus construct with GFP containing Cre gene. 
Adipose Tissue Macrophages (ATMs) Depletion                                                      
Adipose tissue explant pieces were incubated in DMEM (Invitrogen) without serum 
supplementation. After 4 hours, fresh media were added with 20% liposome containing 
either clodronate or PBS. Explants were maintained for 24 hours at 37°C in a carbon 
dioxide incubator. After 24 hours, tissue pieces were collected and immediately froze in 
liquid nitrogen for RNA extraction and fixed in zinc-formalin fixative (Anatech Ltd.) for 
histology purpose. 
Quantitative RT-PCR                                                                                                        
RNA was extracted from frozen adipose tissue samples by using an acid-phenol reagent 
(TRIZOL; Invitrogen). RNA was isolated by using the QIAGEN RNeasy Minikit 
(QIAGEN) and used as template for cDNA synthesis using qScript cDNA SuperMix 
(Quanta Biosciences). Quantitative RT-PCR was performed using DNA Engine Opticon 
2 system instruments (Bio-Rad) and PCR SYBR Green I QuantiTect Master Mix 
(Qiagen). The mRNA expressions of all genes were normalized to the rps3 gene 
expression. DDCT-2 method was used to analyze and present in relative transcriptional 
level. 
Flow Cytometry 
Stromavascular cells were isolated from lean and obese perigonadal adipose tissue (X. 
Xu et al., 2013) and collected in FACS buffer (PBS, 0.2%, fatty acid depleted-BSA, 5 




(BD Pharmingen) and then for an additional 30 minutes with antibodies conjugated with 
fluorophores. The following antibodies were used to sort cells: Cd45.2-Percp-Cy5.5 (BD 
Pharmingen), F4/80-APC (AbD Serotec), CD11b-PE (eBioscience), CD11c-PETR 
(eBioscience), Cd3e-PE (eBioscience), Cd31-PE. After incubation with primiary 
antibodies, the cells were washed twice with FACS buffer and were re-suspended in 
FACS buffer containing 4’, 6-diamidino-2-phenylindole dihydrochloride (DAPI). 
Immune cells and non-immune cells were identified as macrophages: 
Cd45.2+F4/80+CD11b+ (FB) or Cd45.2+F4/80+CD11b+CD11c+ (FBC); monocytes: 
Cd45.2+CD11b+; lymphocytes: Cd45.2+Cd3e+; endothelial cells:Cd45.2-Cd31+; non-
immune cells: Cd45.2-Cd31-. 
Body Compositions                                                                                                                                                
Body composition was measured as fat, lean, and fluid mass by using miniSpec TD NMR 
analyzer (Bruker). 
Metabolic Parameters                                                                                                    
Serum insulin was measured by using ultra sensitive ELISA (ALPCO). Serum IGF1 was 
measured by using IGF1 radioimmunoassay kit (Mediagnost) and IGF1 ELISA (R&D 
system). Serum FFA level was determined by using the HR NEFA series (Wako 
Diagnostics). Serum glycerol was measured by using free-glycerol reagent (Sigma). TG 
level was determined by using TG reagent kit (Fisher Scientific). Glucose tolerance tests 
(GTT) were performed by intraperitoneally injecting glucose (2g of glucose per 
kilogram) collected blood after 20-, 40-, 60-, 90-, and 120-minute after the injection to 
measure glucose concentration in serum. Insulin tolerance tests (ITT) were done by 




after 20-, 40-, 60-, 90-, and 120-minute after the injection to measure glucose 
concentration in serum. 
Adipose Tissue Histology                                                                                               
Adipose tissue was fixed in zinc-formalin fixative (Anatech Ltd.) for 48 hours. After 
fixation, tissues were incubated in 70% ethanol for 24 hours and then embedded in 
paraffin. 5-um sections were cut 50-um intervals and were mounted on glass slides. The 
mounted tissue sections were deparaffinized in xylene, and stained for F4/80 with a rat 
anti-mouse F4/80 monoclonal antibody (Abd Serotec). Sections were incubated with the 
primary antibody for 80 minutes at room temperature (1:100 dilution) and rat IgG2a 
(Invitrogen) was used as isotype control (1:50 dilution). Then a biotinylated anti-rat 
secondary antibody was used (1:200 dilution) followed by the Avidin DH: biotinylated 
horseradish peroxidase H complex (Vector Laboratories) and development in chromogen 
substrate 3,3’’-diaminobenzidine (Vector Laboratories). Subsequently, the slides were 
counterstained with hematoxylin. For the purpose of measuring adipocyte size, the slides 
were only stained with hematoxylin after the 48 hours of fixation in zinc formalin fixative 
(Anatech Ltd). 
Quantification of ATMs                                                                                                     
F4/80 stained adipose tissue section pictures were taken by Image-Pro Plus 7.0 software 
(Media Cybernetics). 4-8 different 20X-power fields per section from each of 4 different 
sections were analyzed per sample. The total number of nuclei and the number of nuclei 
of F4/80-expressing cells were counted for each field. The fraction of F4/80-expressing 
cells for each sample was calculated as the sum of the number of nuclei of F4/80-




Quantification of adipocyte size  
Individual adipocyte cross-sectional area was measured under 20X magnification in each 
field using image analysis software Image-Pro Plus 7.0 (Media Cybernetics).  
Cold Challenge Experiment                                                                                               
Mice were individually housed and fed ad libitum before and during cold challenge. Mice 
were placed in 4 degree Celsius for 3-4 hours to induce an adrenergic stimulus. Rectal 
temperature of mice were monitored and measured by using MicroTherma Handheld 
Thermometer (Braintree Scientific, Inc). Mice were sacrificed immediately after 3-4 

















2.1 Complex Regulation of IGF1 Expression in Adipose Tissue 
   To investigate a potential anabolic factor from adipose tissue macrophages 
(ATMs), we profiled transcripts from purified sub-populations of ATMs. The sub-
populations of ATMs, CD11c- (F4/80+CD11b+) and CD11c+ (F4/80+CD11b+CD11c+), 
were isolated from lean and obese perigonadal adipose tissue (PGAT). Both CD11c- and 
CD11c+ ATMs highly express Igf1, more importantly, obese CD11c+ population shows 
pattern of induction in Igf1 expression relative to lean CD11c+ cells (Figure 2). This 
result again shows that macrophages are the major potential source of adipose tissue 
IGF1.  
 
Figure 2. ATMs highly express Igf1 
Gene expression of Igf1 in purified of adipose tissue macrophages from perigonadal 
adipose tissue of lean and obese (Lep ob/ob) mice. Subpopulations are CD11c- 
(F4/80+CD11b+) and CD11c+ (F4/80+CD11b+CD11c+). Data are represented as mean 
+ SD. n=4/group.  #p=0.08 lean CD11c+ versus obese CD11c+. §p=0.06 obese CD11c- 
versus obese CD11c+. 
 
To determine the quantitative contribution of ATM-derived Igf1 expression in adipose 
tissue, we depleted macrophages by treating whole adipose tissue with clodronate–
encapsulated liposomes. Clodronate is a bis-phosphonate that induces apoptosis when 























apoptosis. PBS-encapsulated liposomes were used as a control. The local depletion of 
ATMs by using clodronate-encaptulated liposomes was verified by 
immunohistochemistry using F4/80 antibodies in the adipose tissue sections. Clodronate 
treated adipose tissue showed ~70% ATM reduction as compare to the PBS treated tissue 





Figure 3. Clodronate-liposome treatment in obese adipose tissue explant depletes 
ATMs. 
A) Immunohistochemistry of adipose tissue macrophages using F4/80 antibody on 
adipose tissue explant sections. B) Quantification of F4/80+ expressing cells in the 
adipose tissue explant sections. Data are presented as mean + SD. n=3 mice/group. 
























Upon ATMs depletion,  as expected F4/80 (Emr1) expression was decreased by 80%, but 
Igf1 expression was unaltered in  adipose tissue from lean animals(Figure 4A). However, 
Igf1 expression in adipose tissue from obese mice,was reduced by 50% along with 
decrease in F4/80 expression after ATM depletion (Figure 4B). Consistent with our 
hypothesis, in lean animals, macrophage-derived IGF1 contributes minimally to adipose 
tissue Igf1 expression whereas in obese animals, macrophage-derived IGF1 represents 





























































A) Gene expression of macrophage specific gene (F4/80) and Igf1 in lean perigonadal 
adipose tissue explants. Data are presented as mean + SD. n=5 mice/group. *p<0.05 
versus PBS treated. B) Gene expression of macrophage specific gene (F4/80) and Igf1 in 
obese perigonadal adipose tissue explants. Data are presented as mean + SD. n=3 
mice/group. *p<0.05 versus PBS treated.   
 
Unexpectedly, the expression of Igf1 was maintained and not higher in adipose tissue 
from obese animals, despite the increase in macrophages and their significant 
contribution to overall Igf1 expression (Figure 5). This argues that the total Igf1 
expression in adipose tissue is maintained and that the relative contribution of different 
cell types switches during the development of obesity.  
 
Figure 5. Obesity does not alter total adipose tissue Igf1 expression 
Gene expression of F4/80 and Igf1 in both lean and obese perigonadal adipose tissue. 
Data are presented as mean + SD. n=3 mice/group. *p<0.05 versus lean mice.  
 
    We hypothesized that while macrophages become a dominant source of IGF1, 
adipocytes reduce Igf1 expression during the development of obesity. To examine Igf1 
expression from adipocytes and ATMs both in lean and obese adipose tissue, we isolated 

































from the SVC by using fluorescent activated sorting, and measured Igf1 expression for 
adipocytes and ATMs. As expected, Igf1 expression of adipocytes was significantly 
reduced in obese mice, whereas Igf1 expression of ATMs was drastically increased, 
suggesting that during the onset of obesity, the dominant Igf1 cellular sources changes 
from adipocytes to ATMs (Figure 6).  
 
 
Figure 6. Obesity leads to cell-type source switch of adipose tissue Igf1 expression  
Gene expression of Igf1 from purified adipocytes and F4/80+ ATMs perigonadal adipose 
tissue from lean and obese (diet-induced obese, DIO). Fluorescent activated cell sorting 
was used to purify adipocytes fraction and F4/80+ ATMs. Data are presented as mean + 
SD. n=5 mice/group. *p<0.05 versus lean mice.  
 
      To study other potential cellular sources of IGF1 in adipose tissue, we purified 
immune cell populations including ATMs and non-immune cell populations, and 
measured Igf1 expression (Figure 7). Relative to adipocytes and ATMs, other cell 
populations expressed negligible amount of Igf1, except for non-immune cells. The non-
immune population of cells in adipose tissue is largely composed of pre-adipocytes and 
































not change with the onset of obesity but the relative contribution by the major sources - 




Figure 7. Adipocytes, ATMs and non-immune cells contribute to adipose tissue Igf1 
expression 
Gene expression of Igf1 in distinctive purified cell populations from lean and obese 
perigonadal adipose tissue. Data are presented as mean + SD. n=5 mice/group.   
 
          IGF1 is critical for adipose tissue development and potentially could regulate 
adipocyte lipolysis. We hypothesized that in lean animals, pre-adipocyte and adipocytes-
derived IGF1 dominate in the regulation of adipocyte development, survival and lipid 
metabolism. In obese animals, however, we posited that adipose tissue macrophage 
derived IGF1 plays a critical if not dominate role in adipocyte hypertrophy, hyperplasia, 






























































2.2- Macrophage derived-IGF1 is not required for adipose tissue development in 
lean animals. 
           To assess the role of macrophage-derived IGF1 in adipose tissue development and 
lipid metabolism we generated mice with myeloid-specific deletion of Igf1. This was 
accomplished by intercrossing a Lyz2 gene which contained a knock in of the Cre-
recombinase (Lyz2-Cre) with a line of mice carry a Igf1 gene in which the exon 4 is 
floxed  (Clausen, Burkhardt, Reith, Renkawitz, & Forster, 1999; J. L. Liu et al., 1998).  
Mice carrying the Lyz2-Cre allele only express the recombinase in myeloid cells, 
however its expression in ATMs had been investigated. Based on our microarray 
expression data of purified immune cells in adipose tissue, ATMs but not adipocytes or 
non-immune cells express the recombinase in the Lyz2-Cre line of mice.  One 
complication to our planned deletion strategy was that both the Lyz2 and Igf1 genes 
reside on chromosome 10, separated by ~ 20 centimorgans.  To overcome this we 
generated mice with a chromosome that contained both the Lyz2-Cre and Igf1 fl/fl alleles.  
In our experiments we crossed Igf1 fl/fl and Igf1fl, Lyz2-Cre;Igf1 +, Lyz2 +.  This 
generated control Igf1 fl/fl mice and Igf1 fl/fl; Lyz2-Cre/+ (Mac-IKO ) mice that lacked 
Igf1 in myeloid cells.   
In lean male mice, body weights and nose-to-anus body lengths of Mac-IKO was 
not significantly different from control littermates (Figure 8). Fat mass, lean mass, and 
fluid mass were not different between the Mac-IKO and control mice (Figure 9A). 
Consistent with unaltered body compositions, subcutaneous adipose tissue (SCAT), 




other organ weights, were unaffected (Figure 9B). In addition, serum IGF1 concentration 
was the same in Mac-IKO and control mice (Figure 9C).  
We also studied adipose tissue histology in Mac-IKO mice by staining paraffin 
embedded adipose tissue sections with H&E staining. We measured size of adipocytes 
from the H&E stained tissues (Figure 10). Lack of IGF1 in ATMs has no effect in 
lipolysis and in number and size of subcutaneous and perigonadal adipocytes. We found 
no significant differences in F4/80 and Igf1 gene expression between PGAT and SCAT 
of Mac-IKO and control mice, showing that ATMs are not the primary contributor of 
adipose tissue Igf1 expression (Figure 11A). As expected these results demonstrate that in 































Figure 8. ATM-derived IGF1 is not essential for normal growth in lean mice 
A)Body weights of 6- to 24-week-old male mice. B)Body length of 16-week-old male 
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Figure 9. ATM-derived IGF1 is not required for systemic tissue growth 
A)Body composition of 24-week-old male mice as measured by MRI. n=9-16 per 
genotype B) Organ weight of 24-week-old male mice. n=9-16 per genotype. C)Fasting 




















































          To determine whether ATM-derived IGF1 regulates lipolysis in lean animals, 24-
week-old lean male Mac-IKO  and control mice were fasted overnight. Then we 
measured the concentrations of serum free fatty acid (FFA) and glycerol as markers for 
lipolysis. As shown in Table 1, FFA and glycerol concentrations did not differ between 
Mac-IKO and control mice.  Insulin powerfully regulates lipolysis of adipocytes but there 
was no compensatory increase in circulating insulin concentration or alteration in glucose 
in the fasted state. We also observed unaltered lipogenesis-and lipolysis-related gene 
expressions in PGAT and SCAT of Mac-IKO adipose tissue as compare to control mice 
(Figure 11B). Together these data argue that ATM-derived IGF1 does not have a 
measurable effect on lipolysis in lean mice.  
 
 
 Control   Mac-IKO    p-value 
FFA 
(mmol/L) 
1.044 ±0.180 0.872 ±0.210 0.044 
Glycerol  
(mg/mL) 
0.015 ±0.004 0.018 ±0.007 0.152 
TG (mg/dL) 55.559 ±15.71 63.856 ±22.33 0.29 
Insulin 
(ng/mL) 
0.543 ±0.105 0.582 ±0.258 0.618 










Figure 10. ATM-derived IGF1 is not required for adipose tissue development 
A) PGAT histology  (hemotoxylin and eosin stained) of 24-week-old lean male mice and 
quantification of perigonadal adipocyte size. Data are presented as mean + SD. n=9-16 
per genotype. B) SCAT histology of 24-week-old lean male mice and quantification of 


































































Figure 11. ATM-derived IGF1 does not regulate white adipose tissue lipogenesis and 
lipolysis in lean mice. 
A)Macrophage marker, F4/80, and Igf1 mRNA gene expression of 24-week-old lean 
male mice in PGAT and SCAT. Data are presented as mean + SD. n=9-16 per genotype. 
B)Lipogenesis- and lipid-related mRNA gene expression of 24-week-old lean male mice 


















































































































2.3- Adipocyte derived-IGF1 is not required for adipose tissue development in lean 
animals. 
             In our model local production of IGF1 regulates adipocyte survival, development 
and metabolism, but unlike macrophages, which contribute little to adipose tissue Igf1 
expression in lean animals, adipocytes are a major source. We therefore hypothesized that 
adipocyte-specific deletion of Igf1 (Adipo-IKO) would impair adipose tissue 
development and increase lipolysis in lean animals.  To test this , we generated Adipo-
IKO mice by crossing Igf1 fl/fl and with a line of mice carrying a Cre recombinase 
transgene driven by the adipocyte-specific Adiponectin promoter (Adipo-Cre mice).  
 As expected the expression of Igf1 was measurably reduced; in PGAT of Adipo-IKO the 
expression of Igf1 was reduce by ~ 75% compared to PGAT from control littermates.  
Similarly, we found a ~80% reduction in Igf1 expression in SCAT from Adipo-IKO 
compared to lean littermate control animals.  However, contrary to our predictions we did 
not detect any difference in the expression of genes involved in lipid metabolism and 
adipocyte differentiation.              
             We also measured the body weights of male lean Adipo-IKO mice We found no 
significant differences in body weight or body length between WT and Adipo-IKO 
(Figure 12).  At age of 26-week-old, we fasted mice for 6 hours, sacrificed the animals 
and measured body composition and tissue weights. We found no significant differences 
between Adipo-IKO and control  (Igf1 fl/fl) littermate mice (Figure 13).  In addition, we 
found no effect of deleting Igf1 in adipocytes on circulating measures of lipolysis or 









Figure 12. Adipocyte-derived IGF1 is not required for normal development in lean 
mice 
A )Body weights of 12- to 26-week-old male mice. B) Body length of 26-week-old male 




































Figure 13. Adipocyte-derived IGF1 not required for systemic tissue growth. 
A)Body composition of 26-week-old male mice as measured by MRI. n=5 per genotype 


































Table 2. Fasting Serum Parameters in 20-week-old lean mice 
 
Despite the drastic decrease in Igf1 expression in adipose tissue in Adipo-IKO mice, we 
found no significant differences in adipose tissue histology and lipogenesis- and 
lipolysis-related gene expressions (Figure 14 and 15). These data suggests that adipocyte-














TG (mg/dL) 24.513  ± 3.103  23.389  ± 3.486  0.6053  
Glycerol (mg/
mL) 0.024  ± 0.011  0.019  ± 0.012  0.4801  
FFA (mmol/L) 0.751  ± 0.105  0.661  ± 0.049  0.1353  
insulin (ng/
mL) 0.528  ± 0.239  0.448  ± 0.179  0.5664  
glucose (mg/
dL) 118.6  ± 18.8  139.8  ± 11.2  0.0696  








Figure 14. Adipocyte-derived IGF1 is not required for adipose tissue development 
A)H&E stained PGAT histology of 26-week-old lean male mice and quantification of 
perigonadal adipocyte size. Data are presented as mean + SD. n=5 per genotype. B)H&E 
stained SCAT histology of 26-week-old lean male mice and quantification of 

































































































Figure 15. IGF1 from adipocytes does not regulate white adipose tissue lipogenesis 
and lipolysis in lean mice 
A)Macrophage marker, F4/80, and Igf1 mRNA gene expression of 26-week-old lean 
male mice in PGAT and SCAT. Data are presented as mean + SD. *<0.05, n=5 per 
genotype. B)Lipogenesis- and lipid-related mRNA gene expression of 26-week-old lean 




















































































































2.4- Macrophage derived-IGF1 is not required for hypertrophy of adipose tissue in 
obese animals. 
 
 Our preliminary data revealed that during the development of obesity, ATMs 
become the dominant source of adipose tissue IGF1.  Based on this observation we 
hypothesized that ATM-derived IGF1 modulates adipose tissue development and 
metabolism when animals become obese. To determine whether ATM-derived IGF1 
regulates adipose tissue hypertrophy & hyperplasia in obesity, we fed Mac-IKO mice a 
high-fat-diet (Research Diet, 60% fat) starting at 8-week-old for 38 weeks and monitored 
their body weights, fat mass, lean mass, fluid mass, and measures of lipolysis metabolic. 
The obese Mac-IKO mice exhibited no significant differences in body weights, body 
compositions, and metabolic parameters in young- and old-aged obese mice (Figure 16 
and Table 3). To examine whether ATM-derived IGF1 modulate systemic glucose 
homeostasis, we performed glucose tolerance test and insulin tolerance test. Consistent 
with fasting serum measures of glucose homeostasis, we found no significant difference 
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Figure 16. ATM-derived IGF1 is not required for systemic growth in obese animals 
A)Body weights of 4- to 45-week-old male mice. Mice were fed a high-fat diet from 5-
week of age (n=8-15 per genotype). B) Body composition of 45-week-old male mice 
(n=5-6 per genotype). C) SCAT, PGAT, and liver weights of 45-week-old male mice 
(n=5-6 per genotype). D)Fasting serum IGF1 concentration in obese 12-week-old male 
















































































































Figure 17. ATM-derived IGF1 does not regulate systemic glucose homeostasis in 
obese mice 
Glucose tolerance tests were performed in obese mice by intraperitoneally injecting 
glucose (2g of glucose per kg). Blood glucose concentrations were measured after 20-, 
40-, 60-, 90-, and 120-minute after the glucose injection Insulin tolerance tests were 
performed on obese mice by intraperitoneally injection of insulin (U of insulin per kg).  
Serum was collected 20-, 40-, 60-, 90-, and 120-minute after insulin injection (n=8-15 per 




  WT   Mac-IKO p-value 
FFA  
(mmol/L) 0.925 ± 0.08 0.879 ± 0.13 0.346 
Glycerol 
(mg/mL) 0.038 ± 0.01 0.043 ± 0.01 0.347 
TG (mg/dL) 32.866 ± 9.05 31.825 ± 10.75 0.822 
Insulin  
(ng/mL) 3.593 ± 0.28 3.583 ± 0.314 0.944 
Table 3. Overnight Fasting Serum Parameters in 36-week-old obese mice 
 
We observed no differences in SCAT and PGAT in obese Mac-IKO mice (Figure 16C). 
Igf1 expression and IGF1 protein level in total perigonadal adipose tissue, in addition to 
serum IGF1 concentration, were unaltered in Mac-IKO mice (Figure 16 and Figure 18). 
These results show that total adipose tissue Igf1 expression is maintained in a state of 
chronic induction of basal lipolysis, despite ATM-derived IGF1 is ablated. Potentially, 




Igf1 is genetically ablated in ATMs. We did not find any significant alteration in adipose 
tissue histology in obese Mac-IKO mice (Figure 19). Collectively, ATM-derived IGF1 




























Figure 18. ATM-derived IGF1 is not major contributor of adipose tissue Igf1 
expression in high-fat fed obese mice 
A)Gene expression of F4/80 and Igf1 of high-fat fed obese mice in PGAT. n=5-6 per 
genotype. Data are presented as mean + SD 
B)Total IGF1 protein level of high-fat fed obese mice in PGAT as measured by ELISA. 































































Figure 19. IGF1 from ATMs does not regulate adipose tissue development during 
the development of obesity 
H&E stained PGAT histology of 47-week-old obese male mice and quantification of 










































































2.5- Adipocyte derived-IGF1 regulates hyperplasia of perigonadal white adipose 
tissue in obese animals. 
        Another major cellular source of IGF-1 in adipose tissue is adipocytes.  To assess 
the effects of the lack of adipocyte-derived IGF-1 on adipose tissue development and 
metabolic function in obesity, we fed male Adipo-IKO with a high fat diet from 6-week-
old to 48-week-old. We found similar to our other cell-specific deletions of Igf1 no 
significant difference in body weights or fat mass between Adipo-IKO mice and control 
littermate mice (Figure 20A and Figure 20B). However, when we measured each 
individual organ weight after a 6-hours of fast, we found ~40% reduction in PGAT 
weight in Adipo-IKO mice as compare to control mice (Figure 20C).  Igf1 expression in 
PGAT in obese Adipo-IKO compared to control obese mice was reduced by 50% 
compared to control obese mice. Consistent with the gene expression total PGAT IGF1 
protein concentration was significantly reduced in adipose tissue of obese Adipo-IKO 
(Figure 21). Theses data demonstrate that, adipocytes are indeed a major source of IGF1 
in adipose tissue in obese animals.  
       When we quantified adipocyte size in PGAT, we did not find significant difference 
between Adipo-IKO and control mice. However given that the fat mass is reduced by 
40%, this suggests that adipocyte number is reduced per depot (Figure 22). Therefore, 
these data indicates that IGF1 from adipocytes modulates periogonadal adipose tissue 
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Figure 20. Adipocyte-derived does not regulate systemic growth but modulates 
perigonadal adipose tissue mass 
A)Body weights of 4- to 48-week-old male mice. Mice were fed a high-fat diet from 4-
week of age (n=5-7 per genotype). B)Body compositions of 48-week-old male mice 
(n=5-7 per genotype). C)SCAT, PGAT, BAT, liver, and kidney weights of 45-week-old 



















































Figure 21. Igf1 expression and IGF1 protein concentration in PGAT of Adipo-IKO 
mice  
A)Gene expression of F4/80 and Igf1 of high-fat fed obese mice in PGAT. n=5-7 per 
genotype. Data are presented as mean + SD 
B)Total IGF1 protein level of high-fat fed obese mice in PGAT as measured by ELISA. 






































































Figure 22. Adipocyte-derived IGF1 modulates adipocyte hyperplasia in a depot 
specific manner 
A) H&E stained perigonadal adipose tissue of 48-week-old obese male mice and 
quantification of perigonadal adipocyte size. (n=5-7 per genotype). B) H&E stained 
subcutaneous adipose tissue histology of 48-week-old obese male mice and quantification 
of subcutaneous adipocyte size (n=5-7 per genotype).Data are presented as mean + SD.    
 
         
           To investigate whether adipocyte-derived IGF1 regulate systemic glucose 
homeostasis, we performed intraperitoneal glucose and insulin tolerance test (Figure 23). 
We also measured fasting serum lipid and insulin concentration and blood glucose 
concentrations(Table 4).  Although impairment in adipocyte hyperplasia is a 











































































































only marginal and non-significant effect on insulin sensitivity as measured by HOMA-IR.   
This would be consistent with the relatively modest effect of differences in any systemic 
metabolic measurements, arguing that even with significant reduction of PGAT mass 





Figure 23. Adipocyte-derived IGF1 does not regulate systemic glucose homeostasis 
in obese mice 
Glucose tolerance tests were performed in obese mice by intraperitoneally injecting 
glucose (2g of glucose per kg) and blood glucose measured at indicated times following 
injection. Insulin tolerance tests were performed in obese mice by intraperitoneally 
injecting insulin (1U of insulin per kg) and blood glucose concentrations measured at 




































































TG (mg/dL) 10.650  ± 11.423  13.569  ± 6.500  0.5705  
Glycerol 
(mg/mL) 0.029  ± 0.010  0.030  ± 0.003  0.8920  
FFA 
(mmol/L) 0.500  ± 0.139  0.512  ± 0.077  0.8455  
insulin 
(ng/mL) 2.061  ± 0.980  2.813  ± 0.651  0.1204  
glucose 
(mg/dL) 153.3  ± 33.9  168.9  ± 17.8  0.3093  
HOMA-IR 19.382  ± 9.503  29.180  ± 7.458  0.0543  


















2.6- Macrophage derived-IGF1 modulates tissue remodeling in perigonadal white 
adipose tissue under adrenergic stimulus. 
          Recent studies suggest that local lipolytic rates regulate macrophages accumulation 
in adipose and have an anti-lipolytic effect.  For example, during early weight loss when 
lipolysis is highest macrophage content of adipose tissue increases.  In obese animals 
losing weight the effect is even more pronounced with a 30% increase in macrophages in 
the first three days of weight loss (Kosteli et al., 2010). In this context ATMs have a role 
of suppressing lipolysis, so that reductions in ATMs increase lipolysis. Thus, to examine 
whether ATM-derived IGF1 modulate adipose tissue lipolysis under acute stress, we cold 
challenged obese Mac-IKO and control littermate mice. Cold challenge is a physiologic 
means of inducing lipolysis in adipose tissue. During the cold challenge, we monitored 
body temperature in each individual mouse. The body temperature of obese Mac-IKO 
mice was not significantly different from the body temperature of WT mice (Figure 24A). 
        After being at 4 degree Celsius for 3 hours, we measured body weight loss and 
found no difference between obese Mac-IKO and littermate control mice (Figure 24B). 
We sacrificed mice to collect and measure SCAT, PGAT, and liver weight. We found 
~20% reduction in PGAT weight as compare to PGAT from control mice but no weight 
difference in SCAT. When we examined the adipose tissue histology by H&E staining 
and quantifying adipocyte size, we again found no difference in adipocyte size (Figure 
25). It has been previously demonstrated that PGAT, but not SCAT, undergo de novo 
adipogenesis during cold challenge (Q. A. Wang, Tao, Gupta, & Scherer, 2013). The 
newly forming adipocytes appear as early as overnight cold challenge (Q. A. Wang et al., 




expressing cells, proliferate only in gonadal white adipose tissue after adrenergic 
stimulation (Y. H. Lee, Petkova, & Granneman, 2013). These suggest that ATM-derived 
IGF1 perhaps regulate proliferation, differentiation, or survival of adipocytes during cold 
challenge in depot-specific way. An alternative explanation to the reduced PGAT mass 
during cold challenge is that local induction of lipolysis in PGAT.  Although we did not 
find effect in systemic lipolysis as measured by circulating FFA and glycerol 
concentrations, local FFA flux may have been increased and reduced PGAT weight 
without affecting perigonadal adipocyte size, yet, due to slight reduction in mass. Thus, 
although it is difficult to delineate the exact reason of the reduced PGAT mass, overall, 
our current data suggest that ATM-derived IGF-1 is important in tissue remodeling 






















Figure 24. ATM-derived IGF1 regulate adipose tissue mass and liver weight during 
cold challenged state 
A) Body temperature of 46-week-old male mice during a cold challenge for 3 hours at 4 o 
C. B) Body weight loss mice following the cold challenge. C) SCAT, PGAT, and liver 
weights of cold challenged 46-week-old male mice. *<0.05, n= 8-15 per genotype. Data 

































































We also found ~30% increase in liver weight of Mac-IKO compared to control littermate 
mice.  The increase was not due to TG content (Figure 26A). Detailed histologic analysis 
did reveal the presence of fibrotic regions Sirius red staining (collagen staining) in the 
livers of Mac-IKO mice (Figure 26B).  While our studies have focused on adipose tissue, 
Kupffer cells in the liver may provide an important source of IGF1 as an anti-fibrotic 

























Figure 25. ATM-derived IGF1 regulates adipocyte hyperplasia during cold 
challenge in obese animals 
A) H&E stained PGAT histology of cold challenged 46-week-old obese male mice and 
quantification of perigonadal adipocyte size. Data are presented as mean + SD. n=9-16 
per genotype. B) H&E stained SCAT histology of cold challenged 46-week-old lean male 
mice and quantification of subcutaneous adipocyte size. Data are presented as mean + SD. 






















































































Figure 26. ATM-derived IGF1 does not regulate liver lipid content 
A) TG content of liver as measured by Folch method for lipid extraction in 46-week-old 
obese mice. B)Sirius red staining (collagen staining) of liver. Data are presented as mean 






































2.7- Ablation of macrophage-derived IGF1 in adipocyte-IKO mice does not affect 
adipose tissue development and metabolism in obese animals. 
          To investigate whether the combination of macrophage and adipocyte IGF1 
deficiency would further affect adipose tissue development in obesity we employed bone-
marrow transplantation to create adipocyte- and macrophage-IGF1 double knockout 
(DKO) mice. We collected bone marrow cells from male Mac-IKO mice and transplanted 
into female Adipo-IKO mice to generate DKO mice. For control mice, we used bone 
marrow cells from male WT mice and transplanted into female Adipo-IKO mice to 
obtain Adipo-Igf1 KO. Then after 3 weeks of bone marrow transplantation, we started to 
feed mice with a high-fat diet until 33-week-old of age to induce obesity. We confirmed 
successful bone marrow transplantation by measuring deleted region of Igf1 in genomic 
level from white blood cells (Figure 27). 
   
Figure 27. Igf1 deletion in white blood cells 
Genomic DNA was isolated from white blood cells of DKO and Adipo-IKO mice. PCR 
primer was used as we designed in Figure 1. 
 
We found no significant difference between the body weight of DKO and Adipo-IKO 
mice and no effect in tissue weights including PGAT, SCAT, and BAT (Figure 28). The 
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DKO and Adipo-IKO mice (Figure 29). These indicate that additional genetic ablation of 







Figure 28. Additional genetic ablation of IGF1 in macrophages does not affect 
systemic growth 
A) Body weights of 10- to 32-week-old female mice. Mice were fed a high-fat diet from 
13-week of age, 3 weeks after bone marrow transplant (n=4-6 per genotype). B)Tissue 



























































Figure 29. Additional genetic ablation of IGF1 in macrophages does not affect 
adipose tissue 
H&E stained perigonadal adipose tissue histology of 32-week-old obese female mice. 



















2.8- Deletion of total IGF1 in adipose tissue in local system leads to alteration in 
adipose tissue lipogenic and immune gene expression. 
         Since we cannot eliminate many compensatory factors such as circulating IGF1 and 
insulin in in vivo mouse model to examine local IGF1 signaling in adipose tissue, we 
deleted IGF1 in perigonadal adipose tissue in culture system. We surgically removed 
PGAT from lean and obese Igf1fl/fl mice and cut the tissue in 1mm size to do explant 
culture. We then treated the adipose tissue explant with adenovirus-GFP-Cre (ad-GFP-
Cre) to delete Igf1 and used control as adenovirus-RFP (ad-RFP). After the treatment of 
ad-GFP-Cre, we found ~70% of Igf1 gene expression down-regulation in both lean and 
obese Igf1fl/fl mice as compare to the control (Figure 30 and Figure 31). After the 
deletion, we found a pattern of down-regulation of lipogenic and lipolysis-related gene 
expression in lean adipose tissue explant in lean PGAT explant (Figure 30). Furthermore, 
we observed more profound decrease in lipid-related gene, especially in Cebpa and Dgat 
gene expression (Figure 31), suggesting that local IGF1 in adipose tissue regulates 
lipogenic gene expression in adipose tissue. Consistently, it has been previously shown 
that IGF1 signaling is important in lipogenesis during differentiation of human 
mesenchymal stem cells to adipocytes in in vitro system (Scavo et al., 2004).  
           After deleting IGF1 in adipose tissue explant, we also discovered that F4/80 
expression is drastically increased whereas macrophage subpopulation marker, Cd11c 
(Itgax) expression is significantly decreased (Figure 32A). A similar pattern was found in 
lean adipose tissue explants (Figure 32B). These gene expression data implies that 
adipose-derived IGF1 modulates lipid-storing function of ATMs. In another words, IGF1 




Thus, lack of IGF1 without any potential compensatory molecules may have led to 





Figure 30. Lack of Igf1decreases lipid-related genes in lean adipose tissue 
A)Igf1 gene expression in Ad-RFP treated and ad-GFP-Cre treated PGAT explant of 16-
week-old lean Igf1fl/fl. n=4. Data are presented as mean + SD. B) Gene expression of 
lipogenic and lipolysis-related gene expression in PGAT explant of 16-week-old lean 


























































































Figure 31. Local IGF1 modulates lipid-related genes in adipose tissue explant 
A)Igf1 gene expression in Ad-RFP treated and ad-GFP-Cre treated PGAT explant of 18-
week-old obese Igf1fl/fl. n=4. Data are presented as mean + SD. B) Gene expression of 
lipogenic and lipolysis-related gene expression in PGAT explant of 18-week-old obese 






























































































Figure 32. IGF1 deletion ex vivo affects innate immune-related gene expression 
A)Gene expression of inflammatory markers (MCP1, TNFa) and macrophage markers 
(F4/80, CD11b, CD11c, Csf1r) in PGAT explant of 16-week-old lean Igf1fl/fl. n=4. Data 
are presented as mean + SD. B) Gene expression of inflammatory markers (MCP1, TNFa) 
and macrophage markers (F4/80, CD11b, CD11c, Csf1r) in PGAT explant of 18-week-






































































2.9 Deletion of total IGF1 in vivo leads to alteration in lipogenic gene expression   
           To investigate the local function of IGF1 in adipose tissue regardless of cell-type 
source of IGF1, we deleted IGF1 in adipose tissue by locally injecting ad-GFP-Cre in the 
right side of PGAT of lean Igf1fl/fl mice. We also injected ad-RFP in the left side of 
PGAT as for an internal control. We confirmed specific and efficient injection of ad-
GFP-Cre and ad-RFP by measuring GFP expression in both right and left sides of PGAT 
and liver GFP expression (Figure 33A). We observed, however, unaltered Igf1 gene 
expression and the PGAT weights in the ad-GFP-Cre treated tissue, indicating that IGF1 
is well compensated by other cellular sources within adipose tissue upon local deletion of 
IGF1 in vivo (Figure 33B and 33C). Despite no changes in Igf1 expression, we found 
slight induction in lipogenic genes including Pparg, Cebpa, and Adiponectin (Figure 
33D). This suggests that deletion of Igf1 in PGAT triggers compensatory mechanism, 
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Figure 33. Igf1 expression is compensated within perigonadal adipose tissue upon 
deletion of IGF1 in vivo 
A)GFP gene expression in Ad-RFP treated (left side) and ad-GFP-Cre treated (right side) 
PGAT and liver of 14-week-old lean Igf1fl/fl  mice. n=3 B)Igf1 gene expression in Ad-
RFP treated (left side) and ad-GFP-Cre treated (right side) PGAT of 14-week-old lean 
Igf1fl/fl  mice. n=3 C)Ad-RFP treated (left side) and ad-GFP-Cre treated (right side) 
PGAT of 14-week-old lean Igf1fl/fl  mice. n=3 D)Lipogenic gene expression in Ad-RFP 
treated (left side) and ad-GFP-Cre treated (right side) PGAT of 14-week-old lean Igf1fl/fl  













































































































          Although 75% of circulating IGF1 is from liver, deletion of liver-specific IGF1 
does not lead to severe postnatal growth retardation (Sjogren et al., 1999; Yakar et al., 
1999). This indicates that 25% extra-hepatic sources of IGF1 are from other tissues, 
which maintains postnatal development in mice.  The importance of local IGF1 
production in normal development was shown in chondrocyte- or osteoblast-specific IKO 
mouse models (Govoni et al., 2007). The mice had phenotypes of severe postnatal growth 
retardation with unaltered serum IGF1 concentration, suggesting that local action of IGF1 
is critical in tissue growth (Govoni et al., 2007). Additionally, Yaker et al. demonstrated 
that adipose tissue highly express IGF1 as compare to other organs (Yakar et al., 1999), 
emphasizing the notion of local autocrine and paracrine action of IGF1 is perhaps more 
important than endocrine function of IGF1. Furthermore, Bio GPS Novartis microarray 
transcriptional profile showed that bone marrow derived macrophages express IGF1 at 
levels comparable to liver and tissue specific macrophage-derived IGF1 has regulatory 
function in acute injury models. Thus our hypotheses were based on essential function of 
local IGF1, which needs to be delineated in order to understand the complex regulation of 
IGF1 in physiology.  
         One potential candidate of extra-hepatic source of IGF1 is adipose tissue and 
macrophages considering the current literature and our data. Since extensive number of 
ATMs infiltrate into adipose tissue during the onset of obesity, we thought that ATMs are 
primary source of IGF1 in obese adipose tissue in addition to adipocytes. When we 
measured the gene expression of Igf1 in various populations in both lean and obese 




adipocytes, ATMs and non-immune cells are important cellular sources of IGF1 in 
adipose tissue. We found that ATM-derived IGF1 regulates adipocyte hyperplasia during 
cold challenge where as adipocyte-derived IGF1 modulates adipogenesis during a long 
term high fat feeding. 
          We predict that the non-immune cells are adipocyte progenitor cells although 
specific marker should be used to define the population. In the case of Adipo-IKO mice, 
because we used Cre under the promoter of Adiponectin, we have to consider that IGF1 
in pre-adipocytes was also genetically deleted. Our current finding, however, lacks 
quantitative distinction of Igf1 expression in adipocytes versus pre-adipocytes. In order to 
accurately define the relative expression level of Igf1 in pre-adipocytes, the adipocyte 
progenitor cells should be isolated by employing FACS from lean and obese adipose 
tissue and measure the relative expression of Igf1. The functionally well defined marker 
for adipocyte progenitor cells are Lin(-):CD29(+):CD34(+):Sca-1(+):CD24(+) which was 
proven by doing transplantation of this cells into lipodytrophic mice (Church, Berry, & 
Rodeheffer, 2014; Rodeheffer, Birsoy, & Friedman, 2008). The lipodystrophic mice fully 
re-generated white adipose tissue after the transplantation of Lin(-
):CD29(+):CD34(+):Sca-1(+):CD24(+) cells, suggesting the clear adipocyte stem cell 
function in vivo (Rodeheffer et al., 2008). 
           We examined local adipose tissue IGF1 function in local system and systemic 
condition by deleting total IGF1 ex vivo and by locally deleting IGF1 in perigonadal 
adipose tissue in vivo, respectively. We observed a pattern of down-regulation of 
lipogenic gene expression in both lean and obese adipose tissue and found significant 




contrast, we found slight increase in Pparg and Adiponectin gene expression level 
without alteration in total Igf1 expression level. These results indicate that without serum 
factors that exist in vivo such as insulin and circulating IGF1, adipose IGF1 directly 
regulate lipogenic gene expression and perhaps inhibit lipolysis in CD11c+ ATMs. 
Additionally, unaltered total Igf1 expression in vivo deletion of IGF1 indicates that upon 
deletion of IGF1 in adipose tissue other cellular sources may compensate for the lack of 
IGF1 in adipose tissue in vivo in acute deletion condition.  
          Taken together, IGF1 regulation is rather complex in vivo as we and other groups 
showed. Endocrine function of IGF1 is less attributable for postnatal development 
whereas local action of IGF1 is critical for maintaining tissue function and development 
(Govoni et al., 2007; Lalancette-Hebert et al., 2007; Lu et al., 2011; Zhao et al., 2000). 
We focused our study in defining local sources and function of IGF1 in adipose tissue. It 
has been previously shown that IGF1 signaling in adipose tissue is very important so that 
genetic ablation of IGF1R in adipose tissue leads to overcompensated expression of IGF1 
in adipocytes (Kloting et al., 2008). Consistently, upon the local in vivo deletion of IGF1 
in PGAT using ad-GFP-Cre, the total Igf1 expression did not change, suggesting that 
important homeostatic maintenance of Igf1 expression occurs in adipose tissue in the 
state of deficiency of IGF1. Therefore, Igf1 expression in adipose tissue is complex and 
dynamically regulated and local adipose IGF1 is necessary in the setting of remodeling 
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Chapter 3: The Role of Lipolysis in Adipose Tissue Macrophage Lipid Content 
Introduction 
  In mammals, during periods when energy intake exceeds expenditure excess 
calories can be stored as triglycerides (TGs) within lipid droplets of adipocytes.  When a 
mammal enters negative energy balance the triglycerides are liberated as free fatty acids 
and glycerol and enter the circulation where they can be taken up by tissues and used as 
substrates to generate ATP and NADPH. Lipolysis is the process by which TGs are 
hydrolyzed into FFAs and glycerol.  In mammals, three neutral lipases responsible for 
lipid droplet TG hydrolysis have been identified:  Hormone sensitive lipase (LIPE/HSL) 
adipose tissue lipase (PNPLA2/ATGL) and Monoacylglycerol lipase  (MGLL/MGL)  
(Nielsen et al., 2014; S. Wang et al., 2008; Zechner et al., 2009; Zechner et al., 2005). 
Although HSL was thought to be the the rate-limiting lipase in lipid droplet TG lipolysis, 
the identification of the generation of HSL-deficient mice raised questions as to whether 
there were other, possibly dominant lipase.  Mice deficient in HSL did not have 
hypertrophic adipocytes or reduced rates of lipolysis (Osuga et al., 2000; S. P. Wang et 
al., 2001).  Indeed, HSL was found to preferentially hydrolyze DG yielding MG as 
evidenced by the fact that HSL-deficiency increased DG in adipose tissue (Haemmerle, 
Zimmermann, Hayn, et al., 2002). In 2004, three independent groups discovered a novel 
lipase that was dubbed adipose triglyceride lipase or desnutrin, which specifically 
catalyze the initial step of lipolysis acting on TG to release DG and a single FFA (Jenkins 
et al., 2004; Villena et al., 2004; Zimmermann et al., 2004). Elegant genetic studies in 




regulated – induced by adrenergic stimuli and glucagon. Currently, there is no evidence 
for hormonal regulation of MGL activity (S. Wang et al., 2008).  
This process of catalyzing neutral lipid in adipocytes and releasing FFA into 
circulation is essential to maintain energy homeostasis during fasting, exercising, and 
cold challenge (Kolditz & Langin, 2010; S. Wang et al., 2008; Zechner et al., 2005). 
During the above mentioned negative energy balance state, FFA becomes the critical 
energy source for other metabolically active organs. In addition to physiologic responses 
to acute stimuli, lipolysis in fat is also increased in obesity and is implicated in the 
ectopic accumulation in other tissues and the development of insulin resistance. During 
the onset of obesity, the increased volume of adipocyte TG is associated with an increase 
in basal lipolysis. The excessive concentration of FFA has been often implicated as a 
major contributor of local and systemic inflammation and insulin resistance (Boden, 
2003, 2011; Boden et al., 2005). Thus, the optimum balance of lipolysis rate is critical to 
maintain lipid and glucose homeostasis. The function of lipolysis and metabolic 
disturbances has been also implicated in innate immune response (Hotamisligil, 2006; 
Kosteli et al., 2010). Kosteli et al. showed that upon stimulation of lipolysis through 
physiological, pharmacological, and genetic means, macrophages accmulate in adipose 
tissue. ATM recruitment was correlated with increase in serum FFA concentration, 
implicating FFA is a mediator of immune system activation in obesity. In addition, Li and 
Renier showed that adipocyte-derived lipoprotein lipase (LpL) induces macrophage 
inflammatory activation, which ultimately induces monocyte adhesion to endothelial cells 
in vitro (Li & Renier, 2007). They predicted that FFA produced by hydrolysis of 




described an adaptive function for ATM.  They found that increases in lipolysis led not 
only accumulation of ATMs but also their accumulation of neutral lipid, which they 
postulated protected surrounding cells from the toxic effects of FFA as a lipotoxic 
buffering mechanism. Although their perspectives on effect of ATM’s response to FFA is 
different, both of these studies suggest that FFA released from lipolysis is the mediator of 
macrophage recruitment to adipose tissue. The role of macrophages in lipid metabolism 
has been previously studied in the development of atherosclerosis. During the early 
stages of atherogenesis, monocytes migrate to the intimal region of arteries where they 
uptake low-density lipoproteins (LDL) or modified LDL.  As atherosclerosis progresses 
the monocytes take up residence and become cholesterol-rich macrophages, foam cells 
(McLaren, Michael, Ashlin, & Ramji, 2011). Excessive amount of native LDL uptake 
and the modified LDL (oxidized LDL, aceylated LDL, and glycylated LDL) occurs via 
LDL receptor (LDLr) and cholesterol transporters in foam cells, respectively (Moore & 
Freeman, 2006). Additionally, aggregated LDL and modified LDL are ingested through 
phagocytosis or macropinocytosis (N. L. Jones & Willingham, 1999; McLaren et al., 
2011).  
In adipose tissue, however, though it has been shown that FFA drives ATM 
recruitment, little had been known about the mechanisms of lipid uptake and metabolism 
by ATMs. Xu et al. recently demonstrated that a subpopulation of ATMs, CD11c+ ATMs 
(FBCs), have an important functional role in lipid metabolism via lysosomal degradation 
of neutral lipids (X. Xu et al., 2013) and Huang et al. showed that M2 macrophage 
phenotype requires lysosmal lipase activity (Huang et al., 2014). These studies uncovered 




inflammation. However, the specific mechanism of lipid ingestion, trafficking, 
metabolism, and efflux is yet to be studied.  Since we have previously shown that 
lipolysis drives ATM recruitment and role of ATMs in lipid metabolism (Kosteli et al., 
2010; X. Xu et al., 2013), we hypothesized that lipolysis modulates ATM lipid uptake. 
Previous studies in which ATGL has been deleted in the whole body of mice or in Ap2-
promoter driven manner (adipocytes, macrophages and certain brain regions) increased 
adipose tissue mass (Ahmadian et al., 2011; Haemmerle et al., 2006).  However, the 
effect on ATMs was not characterized.  
To test our hypothesis, we generated adipocyte-specific Atgl deficient mice 
(AAKO). We studied metabolic parameters of lean and obese of AAKO by measuring 
body weights, adipose tissue weights, and serum metabolites and hormones. We 
specifically studied ATMs in perigonadal adipose tissue (PGAT) both in lean and obese 
animals by flow cytometry analysis. We predicted that the AAKO mice would have 
fewer FBC cells and  those that were present would have lower lipid content in AAKO 













Animal and Animal Care 
C57BL/6J mice that express the Cre-Recombinase specifically in adipocytes 
under the control of the Adiponectin promoter were generated by Evan Rosen and kindly 
provided to us (Eguchi et al., 2011). Mice carrying a floxed allele of Pnpla2/Atgl  
(C57BL/6J Atgl fl/fl ) were kindly provided by Erin Kershaw (University of Pittsburgh). 
All mice were housed in ventilated Plexiglas cages within pathogen-free barrier facility 
maintained in a 12-hour light/12-hour dark cycle. To induce obesity, the male mice were 
fed with a high-fat diet (60% kcal high fat, Research Diet, Inc). All protocols were 
approved by the Columbia University International Animal Care and Use Committee. 
 
Generation of adipocyte-specific ATGL KO mice (AAKO) 
To generate mice that lacked Atgl/Pnpla2 in adipocytes, we intercrossed the 
Adiponectin-Cre transgene into the background Atglfl/fl to generate two genotypes of 
mice Adiponectin-Cre+; Atgl fl/fl  (AAKO) and Atgl fl/fl  (control). 
 
Flow Cytometry 
Stromavascular cells were isolated from perigonadal adipose tissue of lean and 
obese (X. Xu et al., 2013) and collected in FACS buffer (PBS, 0.2%, fatty acid depleted-
BSA, 5 mM EDTA). The cells were incubated in the dark for 30 minutes with 0.5mg/ml 
FcBlock (BD Pharmingen) and then for an additional 30 minutes with antibodies 
conjugated with fluorophores at 4 degree Celsius. The antibodies to the following 




(AbD Serotec), CD11b-PE (eBioscience), CD11c-PETR (eBioscience), Bodipy-FITC 
(Life Technologies). After incubation with primiary antibodies, the cells were washed 
twice with FACS buffer and were resuspended in FACS buffer containing 4’, 6-
diamidino-2-phenylindole dihydrochloride (DAPI). Previously described subpopulations 
of ATMs were identified as: CD45.2+F4/80+CD11b+ (FB) or 
CD45.2+F4/80+CD11b+CD11c+ (FBC). Quantitative percentage of Bodipy in each 
ATM population was indicated as amount of neutral lipids. LSRII (BD Bioscience) was 
used for cell sorting and FlowJo Software was used to analyze the data. 
 
Body Compositions                                                                                                                                              
Body composition was measured as fat, lean, and fluid mass by using miniSpec TD NMR 
analyzer (Bruker). 
Metabolic Parameters                                                                                                    
Serum insulin concentration was measured using an ultrasensitive ELISA (ALPCO). 
Blood glucose concentration was measure using the glucose dehydrogenase gluconate 
reaction (FreeStyle Lite glucose meter and test strips -Abbott).  Serum FFA concentration 
was determined using the HR NEFA series assay (Wako Diagnostics). Serum glycerol 
was measured using the free-glycerol reagent (Sigma). TG concentration was determined 
using the TG reagent kit (Fisher Scientific). Glucose tolerance test (GTT) was performed 
by intraperitoneally injecting glucose (2g of glucose per kilogram) and blood glucose was 






Pharmacologically induced lipolysis   
Male mice were intraperitoneally injected with beta-3-adrenergic agonist (CL316, 
243 1mg/kg of Sigma) or saline twice (4 hours between each injection). Mice were 
sacrificed 14 hours after the second injection. Tissues were collected and samples 






















3.1- Genetic deletion of adipose tissue triglyceride lipase (ATGL) increases white 
and brown adipose tissue mass in lean animals  
              To investigate the effects of impairing adipocyte lipolysis we generated  mice 
that lacked Atgl in adipocytes by intercrossing  an adipocyte specific Cre-recombinase 
transgene with mice carrying Atgl fl/fl alleles. We confirmed specific and efficient 
deletion of ATGL in adipose tissue by measuring ATGL mRNA gene expression in both 
PGAT and BAT (Figure 1).  To determine whether adipocyte-specific deletion prevented 
demand lipolysis as predicted, we measured serum FFA and glycerol concentrations after 
pharmacologic stimulation of adipose tissue lipolysis. We used β3-adrenergic agonist, CL 
316, 243 (Sigma), which activates lipolysis specifically in adipocytes. Interestingly, in 
the fed state serum FFA and glycerol concentrations were not affected by the deletion of 
Atgl. In another words, we did not observe differences in circulating measures of basal 
lipolysis (serum FFA and glycerol concentrations).  However, as predicted fat specific 
demand lipolysis induced by the injection of a β3-adrenergic agonist was completely 
blocked in AAKO mice (Figure 2). After confirming deletion of Atgl in adipose tissue, 
we began to characterize the animals metabolically.  
             We measured body weights of male and female mice from 7- to 12-week. We 
found that both female and male AAKO mice control weighed more than littermate 
control mice (Figure 3). Specifically fat mass, but not lean and fluid mass, was higher in 
both female and male AAKO mice than in control animals (Figure 4).  All depots we 
examine in AAKO mice, both white and brown adipose tissue were larger in AAKO 
compared to control mice, with the exception of PGAT in male mice which weighed the 




with the whole body and Ap2-driven deletion of Atgl, though the differences were larger 
in our adipocyte-specific deletion (Ahmadian et al., 2011).   
In addition to the increase in adipose tissue depot mass, the liver weight of female 
AAKOmice was less than of female control mice, whereas liver mass of male AAKO 
lean mice was unaffected by the deletion of ATGL (Figure 5 and Figure 6). The reason 
for the difference in phenotypes of PGAT from female and male remains unclear, but 
given the sexual dimorphic distribution of fat in wild-type mammals, these finding 
suggest that differences in lipolytic capacity may underlie some of the differences. .  
Although AAKO mice possessed more adipose tissue, we expected that the 
reduction in lipolysis in these animals would protect them from insulin resistance.  
To study systemic glucose metabolism in AAKO lean animals, we performed GTT both 
in females and males. We observed significant reduction in serum glucose level after 6-
hour-fasting (Figure 7). After 60-minutes of glucose challenge, AAKO mice showed 
drastic decrease in blood glucose concentrations as compare to control mice (Figure 7), 
suggesting that lack of ATGL leads to shifting to glucose utilization not only during 
fasting but also when system insulin concentration is high and would be expected to 
suppress lipolysis. 
Taken together our data argue that adipocyte ATGL plays a critical role in lipid 
and glucose metabolism in lean animals. As shown in the data, adipocyte-specific ATGL 
deletion drastically increased the mass of white adipose tissue and brown adipose tissue. 
Brown adipose tissue showed a more profound effect than white adipose tissue, 




important in brown adipocyte development as well. Therefore, changes in brown adipose 







Figure 1. Efficient deletion of fat-specific ATGL 
A)Atgl expression measured in PGAT of female (left) and male (right) lean animals. B) 
Atgl expression measured in BAT of female lean mice (n=6-12 per genotype for female 




































































































Figure 2.  Adipocyte-specific ATGL’s effect on lipolysis in lean animals 
A)Serum FFA concentration measured in 13-week-old female and male mice after i.p. 
injection of CL 316, 243. (n=6-12 per genotype in female group. n=4-8 per genotype in 
male group. *p<0.05. B)Serum glycerol concentration measured in 13-week-old female 
and male mice after i.p. injection of CL 316, 243. n=6-12 per genotype in female group  
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Figure 3. Lack of adipocyte-specific ATGL increases body weight in young lean 
mice 
A) Body weights of 7- to 12-week-old female mice.B) Body weights of 7- to 12-week-
old male mice (n=6-12 per genotype for female, n=4-8 per genotype for male animals. 















































Figure 4. Genetic deletion of adipocyte-specific ATGL increases fat mass of young, 
lean mice 
A) Body composition of 13-week-old lean female mice as measured by MRI. B) Body 
composition of 13-week-old lean male mice as measured by MRI. (n=6-12 per genotype 








































Figure 5. Adipocyte-ATGL regulates adipose tissue and liver mass in female animals 
Subcutaneous adipose tissue (SCAT), perigonadal adipose tissue (PGAT), brown adipose 
tissue (BAT), and liver weights of 13-week-old female lean mice(n=3-6 per genotype. 
























































Figure 6. Adipocyte-ATGL regulates adipose tissue mass in male animals 
SCAT, PGAT, BAT, and liver weights of 13-week-old male lean mice (n=2-4 per 












































































Figure 7. Adipocyte-specific ATGL ablation increases glucose utilization in lean 
mice 
A) Glucose tolerance tests were performed on 13-week-old female lean mice. (n=6-12 
per genotype). B) Glucose tolerance tests were performed on 13-week-old male lean 































































3.2- Genetic deletion of ATGL reduces subcutaneous white adipose tissue mass but 
increases brown adipose tissue mass in long term high-fat fed animals.  
           Recent studies suggest that in obese animals an intra-adipose tissue lipid cycle 
occurs whereby lipid released by adipocytes is taken up by macrophages and then 
released (Kosteli et al., 2010; X. Xu et al., 2013). By analogy to bone we predict that 
impairment of this process would alter adipose tissue development and function.  When 
old mice (>26 weeks) are fed a high diet they rapidly gain fat mass and become obese.  
To examine the effects of rapid weight gain in the absence of adipocyte ATGL, we 
switched the diets of 36-week-old male mice from low to high fat diet for 5 weeks and 
measured body weight. The body weights of the AAKO and control mice were not 
different (Figure 8).  On the surface these findings suggest that rapid expansion of 
adipose tissue does not require ATGL in adipocytes and does not reveal evidence of an 
intra-adipose tissue lipid cycle in which ATGL is required.  However, given that adipose 
tissue mass is increased in basal, low fat conditions it appeared that Atgl deficiency may 
have limited fat mass expansion during rapid expansion. 
To more closely examine the effects of adipocyte-specific deletion in Atgl on fat 
mass expansion in high fat fed animals we placed 12-week-old lean male on a high fat 
diet for 12 weeks. In contrast to the effects in low fat fed animals the high fat fed AAKO 
mice weighed 20% less than control animals (Figure 9A). The body composition of these 
long-term high fat fed AAKO mice also revealed a significant reduction of fat mass 
compared to their control littermates as measured by MRI (Figure 9B). These unexpected 




increase fat mass and suggests a more complex role for lipolysis in adipose tissue 
expansion and physiology. 
 
Figure 8. Weight gain following short-term high fat feeding 
Body weights of 40-week-old obese mice (n=5-8 per genotype. All data are presented as 
means + SD). 
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Figure 9. Adipocyte ATGL modulate body weight under long term high fat feeding 
A) Body weights of 12- to 48-week-old obese animals. B) Body composition of 24-week-
old animals after 12 weeks of high fat feeding (n=6-9 per group.**p<0.01. All data are 
presented as means + SD). 
 
 
As mentioned above, in mice deficient in HSL adipose tissue lipolysis and 


















































fat feeding led to a relative reduction in adipose tissue mass in AAKO mice, we  
investigated whether the adipocyte-specific Atgl altered basal or demand lipolysis.  To 
test this we measured serum concentrations of glycerol and FFAs in the fed state and 
following intraperitoneal injection of  CL 316, 243 in both short-term and long-term high 
fat fed mice.  
           When we sacrificed the short term high fat fed obese animals, we observed no 
significant effect in body weight and serum glucose concentration (Figure 10). We did 
not observe any change in white adipose tissue weights in AAKO obese mice. We found 
a more than two-fold increase in BAT weight of AAKO obese mice as compare to 
control obese animals, although the CL 316, 243 did not further affect BAT. We also 
observed reduction in liver weight in AAKO obese mice, though again, CL 316, 243 did 
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Figure 10. Adipocyte-ATGL is not required for body weight and glucose 
homeostasis regulation under a short term high fat feeding 
A) Body weights of 40-week-old obese mice with or without CL 316, 243 i.p. injection. 
B) Serum glucose level of 40-week-old obese mice with or without CL 316, 243 i.p. 
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Figure 11. Adipocyte ATGL modulates brown adipose tissue and liver mass under a 
short term high fat feeding 
A) Subcutaneous adipose tissue weights of 40-week-old obese mice with or without CL 
316, 243 i.p. injection. B) Perigonadal adipose tissue weights of 40-week-old obese mice 
obese mice with or without CL 316, 243 i.p. injection. n=2-4 per group. C) Brown 
adipose tissue weights of 40-week-old obese mice obese mice with or without CL 316, 
243 i.p. injection (*p<0.05 control vehicle versus AAKO vehicle. #p<0.05 control 
vehicle versus CL 316, 243 AAKO). D) Liver weights of 40-week-old obese mice obese 
mice with or without CL 316, 243 i.p. injection( n=2-4 per group. *p<0.05 control 
vehicle versus AAKO vehicle. All data are presented as means + SD). 
 
In the case of prolonged high fat fed animals, we found no effect on serum 
concentration of glucose (Figure 12). We discovered significant decrease in SCAT and 
liver weight in AAKO obese mice as compare to control obese animals (Figure 13A and 
Figure 13D). Similarly with lean AAKO and the short term high fat fed male mice, we 
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animals (Figure 13C). We, however, did not find an effect on PGAT weight in AAKO 
obese mice as we observed in lean AAKO animals (Figure 13B). In all tissues, there were 
no additional effects of acute adrenergic activation by CL 316, 243.    
As was observed in young low fat fed animals, we expected to find that deletion 
of Atgl in adipocytes would increase fat mass in high fat fed animals.   However, these 
finding suggest that local flux of FFAs and glycerol out of adipocytes has effects on 
energy balance.  Although we did not measure food intake or energy expenditure, one or 
both of these parameters much be altered to favor a reduced weight in high fat fed AAKO 
mice.  The mechanisms by which this happens are beyond the scope of these studies but 
could reveal important factors released by adipose tissue that regulate whole body energy 
homeostasis. One possibility is that the expansion of BAT may increase energy 
expenditure without compensatory increase in food intake.   
Taken together, prolonged high fat feeding clearly illustrates greater effect than 
short term high fat feeding in AAKO obese mice. Mice with 5-weeks of high fat feeding 
only magnified the phenotype in BAT weight that we found in lean male AAKO mice 
and slightly diminished liver weight in AAKO obese mice as compare to control obese 
mice. Unlike in young lean male AAKO mice where we found significantly bigger SCAT 
weight as compare to control lean mice, SCAT weight was normalized in the short term 
high fat fed AAKO mice as compare to control counterparts. This suggests that a 
stimulus of basal lipolysis may have led to increase in other lipases’ activities as a 
compensatory mechanism. Along with this notion, after the long term high fat feeding, 
AAKO mice exhibited significant reduction in SCAT, indicating that continuous stimulus 




compensatory mechanism, which eventually results in much smaller SCAT in the long 
term high fat fed AAKO mice. However, we also have to consider the importance of 
physiologic regulation of energy expenditure and food intake to explain the altered 
weight in SCAT in obese AAKO mice. If food intake is reduced in obese AAKO mice, 
then this would suggest that impairment in adipocyte lipolysis affect feeding behavior. 
Similarly, if energy expenditure is increased in obese AAKO mice, this implies that lack 
of ATGL in adipocytes alters signals from adipose tissue to the central nervous system. 
Therefore, for the future studies, it would require us to measure food intake, energy 
expenditure, as well as potential deletion of ATGL in brain.  
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Figure 12. Adipocyte ATGL is not required for body weight and glucose 
homeostasis regulation under a long term high fat feeding 
A)Body weights of 48-week-old obese mice with or without CL 316, 243 i.p. injection. 
n=2-4 per group. B)Serum glucose concentration of 48-week-old obese mice with or 














Vehicle" CL"316,"243" Vehicle" CL"316,"243"







Vehicle" CL"316,"243" Vehicle" CL"316,"243"





A                                                                           B 
 
C                                                                              D 
 
Figure 13. Adipocyte- ATGL dependent effects on subcutaneous adipose tissue, 
brown adipose tissue and liver mass under a long term high fat feeding 
A) SCAT weights of 48-week-old obese mice with or without CL 316, 243 i.p. injection. 
n=2-4 per group. B) PGAT weights of 48-week-old obese mice obese mice with or 
without CL 316, 243 i.p. injection. n=2-4 per group. C)BAT weights of 48-week-old 
obese mice obese mice with or without CL 316, 243 i.p. injection. n=2-4 per group. 
*p<0.05 control vehicle versus AAKO vehicle. #p<0.05 control vehicle versus CL 316, 
243 AAKO. D)Liver weights of 48-week-old obese mice obese mice with or without CL 
316, 243 i.p. injection. n=2-4 per group. *p<0.05 control vehicle versus AAKO vehicle. 
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3.3- Genetic ablation of ATGL increases CD11c+ ATM content but decreases ATM 
lipid uptake in lean animals. 
Our primary motivation for these studies was to determine whether adipocyte 
ATGL deficiency altered ATM accumulation and lipid uptake.  We hypothesized that 
both would be reduced in AAKO mice. To investigate whether adipose tissue lipolysis 
modulates ATM recruitment and lipid uptake, we injected 24-week-old lean male mice 
with the beta-3 agonist CL 316,243.  Pharmacologic activation of lipolysis induces a 
large, rapid and consistent influx of ATMs into adipose tissue and lipid accumulation in 
ATMs (Granneman, Li, Zhu, & Lu, 2005; Kosteli et al., 2010; Y. H. Lee et al., 2013; 
Roth Flach et al., 2013). Therefore to assess the effects of adipocyte-dependent ATGL 
lipolysis we treated lean mice with CL 316,243 and assessed systemic metabolic 
phenotypes and adipose tissue immune cell phenotypes in AAKO and control mice. 
Consistent with the previous result in the young 12-week-old lean male animals, AAKO 



















Figure 14. The absence of ATGL-dependent lipolysis does not alter bodyweight or 
fat mass in lean male mice treated with adrenergic stimulus 
A) Body weights of 24-week-old lean male mice., *p<0.05. B)White adipose tissue 
weights of 24-week-old lean male mice. C)Brown adipose tissue and liver weights of 24-
week-old lean male mice (n=4-5 per group. §p=0.06, , *p<0.05. **p<0.01). All p-values 













































































We hypothesized that adipocyte lipolysis drives ATM accumulation and lipid 
uptake. To analyze ATM subpopulations and lipid content in PGAT, we isolated 
stromavascular cells (SVCs) and identified relevant immune cell populations using FACS 
analysis:  all immune cells (anti-CD45.2), all ATMs (anti-F4/80), all myeloid cells (anti-
CD11b) and CD11b+/CD11c- and CD11b+/CD11c+ ATMs (anti-CD11b, and anti-
CD11c).  CL 316, 243 induces rapid myeloid cell recruitment including ATM recruitment 
to PGAT and accumulation of neutral lipid in ATMs. Consistent with past observations, 
CL 316, 243 induced rapid CD11b+ cell infiltration in adipose tissue of control mice 
(Figure 15). However, as predicted the effect of CL 316, 243 on myeloid cell  
accumulation was completely prevented in the AAKO lean mice, indicating that ATGL 
directly regulates total myeloid cell recruitment in PGAT (Figure 15).  
To assess the effects of impaired lipolysis on ATM recruitment and lipid content, 
we used FACS to identify CD11c+ (FBC) and CD11c- (FB) ATMs and the fluorescent 
dye Bodipy-FITC (Life Technologies) that accumulates with neutral lipids.  As a percent 
of all immune cells there was a slight shift of ATMs towards CD11c+ FBC, ie the ratio of 
FBC/FB was increased in AAKO mice compared to control animals, regardless of CL 
316,243 treatment (Figure 16). However, when we analyzed neural lipid in both FB and 
FBC populations by labeling the neutral lipid, we found decrease lipid content in AAKO 
lean animals as compare to ATMs from control counterparts (Figure 17). More 
importantly, while bodipy content was increased in control CL 316, 243 treated mice as 
compare to control vehicle treated mice, this effect was completely absent in CL 316, 243 
treated lean AAKO mice. In lean animals impairment of adipocyte lipolysis increases the 




animals is nearly entirely dependent upon adipocyte lipolysis and likely to proceed by 







Figure 15. Adipocyte-specific ATGL regulates myeloid cell recruitment in PGAT of 
lean animals during adrenergic induced lipolysis 
A) Typical FACS histograms of CD11b+ cells in SVCs of 24-week-old lean male mice.  
B) Average percent of myeloid (CD11b+) cells out of total SVCs in PGAT (n=4-5 mice 
per group, pooled 2 tissue samples to make 1 tube, therefore n=2-3 samples per group. 
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Figure 16. Fat-specific ATGL modulates ATM phenotype in lean animals 
A)Typical FACS scatter SVC plots of F4/80+CD11b+CD11c+ out of total CD45.2+ cells 
in PGAT of 24-week-old lean male mice. B) Bar graphs of averaged percent of 
F4/80+CD11b+ out of all immune  CD45.2+ cells from SVCs in PGAT. n=4-5 mice per 
group, pooled 2 tissue samples to make 1 tube, therefore n=2-3 samples per group. C)Bar 
graphs of averaged percent of F4/80+CD11b+CD11c+ out of total CD45.2+ cells from 
SVCs in PGAT( n=4-5 mice per group, pooled 2 tissue samples to make 1 tube, therefore 
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Figure 17. Fat-specific ATGL regulates ATM lipid uptake in lean animals 
A) Typical FACS histograms of lipid content as measured by bodipy accumulation  in 
FBs of PGAT from 24-week-old male mice.B)Typical FACS histograms of lipid content 
as measured by bodipy accumulation in FBCs of PGAT from 24-week-old male mice C) 
Percent of lipid+ FBs and FBCs in PGAT of 24-week-old male mice (n=4-5 mice per 
group, pooled 2 tissue samples to make 1 tube, therefore n=2-3 samples per group. All 
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3.4- Ablation of ATGL decreases CD11c+ ATM content and ATM total lipid uptake 
in obese animals. 
 
Recent studies from our laboratory have found that with the onset of obesity 
ATMs increase lipid uptake and activate a catabolic program that is lysosomal dependent.  
At least some of the lipid “droplets” appear to be in membrane-bound vesicles, ie not the  
lipid droplet organelle. Furthermore, the catabolism of neutral lipids while mediated by 
lysosomes is not dependent on autophagy arguing lipids in ATMs from obese compared 
to lean individuals reside in a distinct pool with a different metabolic fate.  If they reside 
in a distinct vesicular pool, then their accumulation in adipose tissue may be by a 
mechanism that is phagocytosis dependent and does not require lipolysis and re-
esterification.  To investigate whether adipocyte-specific ATGL modulates ATM lipid 
uptake in obesity, we measured lipid content in ATMs from obese AAKO and control 
mice in the fed state and after β3-adrenergic stimulation.  
            Unlike in lean animals the ratio of FBC:FB was not increased, indeed it was 
decreased compared to ATM populations in control obese animals (Figure 19).  We also 
found a relative increase in total myeloid cells in PGAT from AAKO obese mice but 
surprisingly no induction of myeloid cell content after the injection of CL 316, 243 in 
mice of both genotypes (Figure 18). Because these mice were fed with a high fat diet for 
long time, ATM content in PGAT may have already reached plateau, therefore, further 
recruitment of ATMs was perhaps not possible.  
Similar to ATMs in lean animals, neutral lipid content in both FBs and FBCs was 
significantly lower in obese AAKO as compared to ATMs from obese control animals 
(Figure 20), demonstrating that ATM lipid uptake in the fed state is dependent on 




adrenergic stimulus did increase lipid content of ATMs in AAKO mice. This argues that 
there exists a non-ATGL dependent mechanism to release lipid from adipocytes. The two 
simplest possibilities are that another neutral lipase, eg HSL can increase lipolysis in 
obesity when stimulated with catecholamine or that in obesity a non-lipolytic process can 






Figure 18. Lack of adipocyte-ATGL increases total CD11b+ cells in PGAT of obese 
animals 
A) Typical FACS histograms of CD11b+ cells in SVCs of 50-week-old obese male mice.  
B) Bar graph of averaged percent of CD11b+ cells out of total SVCs in PGAT of 50-
week-old obese male mice (n=2-5 mice per group.  §p=0.124, *p<0.05 relative to control 
vehicle group. All values are means + SD). 
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Figure 19. Adipocyte-ATGL modulates ATM phenotype in obese animals 
A)Typical FACS scatter SVC plots of FBs and FBCs out of total CD45.2+ cells in PGAT 
of 50-week-old obese male mice. B)Bar graphs of averaged percent of FBs out of total 
CD45.2+ cells from SVCs in PGAT. n=2-5 mice per group. *p<0.05, **p<0.01. All p-
values are comparing to control vehicle group. C) Bar graphs of averaged percent of 
FBCs out of total CD45.2+ cells from SVCs in PGAT. (n=2-5 mice per group. §p=0.07, 
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Figure 20.  ATGL independent lipid accumulation in ATMs of adipocyte-ATGL 
deficient obese mice 
A) Typical FACS histograms of bodipy+ in FBs in PGAT of 50-week-old obese male 
mice.B) Typical FACS histograms of bodipy+ in FBCs in PGAT of 50-week-old obese 
male mice. C)Bar graphs of averaged percent of bodipy in FBs and FBCs in PGAT of 50-
week-old lean male mice (n=2-5 mice per group. **p<0.01 versus AAKO vehicle group. 
#p<0.05 versus control vehicle group. All values are means + SD). 
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           During the development of obesity, macrophages accumulate in adipose tissue and 
release pro-inflammatory molecules (Weisberg et al., 2003; H. Xu et al., 2003). Although 
the role of ATMs in inflammation has been extensively investigated over the last decade 
(Lumeng et al., 2007; Olefsky & Glass, 2010; Patsouris et al., 2008), the homeostatic 
function of ATMs in obesity has been less well studied. The current dogma of M1/M2 
polarization of ATMs seems to provide a rather restrictive description of a more complex 
innate immune response to metabolic disturbances because the function of macrophages 
in other organs were involved in normal development and the homeostasis of 
pathophysiological state. In addition, Mosser and Edwards defined function of 
macrophages as in host defense, wound healing, and immune response and explained 
plasticity of macrophage function in various microenvironment (Mosser & Edwards, 
2008). Therefore, the specific function of ATM during the onset of obesity needs to be 
addressed for the clear understanding of the innate immunity under metabolic 
disturbances. 
          Since our previous study demonstrated that lipolysis drives ATM recruitment 
(Kosteli et al., 2010) and the CD11c+ expressing ATMs (FBCs) are involved in 
lysosomal-related lipid metabolism, we decided to investigate whether lipolysis is a direct 
modulator of lipid uptake in ATMs and whether the lipid content in ATMs quantitatively 
affects FBCs. To study regulation of lipolysis in ATM lipid uptake in vivo, we generated 
adipocyte-specific ATGL KO mouse model, AAKO.  Since the mice are novel mouse 
model, we first studied metabolic phenotypes of these mice before we investigate the 




PGAT mass in 12-week-old lean mice. The female AAKO mice had significantly bigger 
PGAT weight as compare to female control PGAT weight, whereas male AAKO mice 
PGAT weight was the same as male control PGAT mass (Figure 3 and 4). The difference 
may be due to the effect of estrous cycle in female mice or sexual dimorphism of ATGL 
gene. Although the specific reason for this needs to be elucidated in the future, we 
decided to use male mice to eliminate unknown hormonal factors in female mice. 
             In male mice, both lean and obese AAKO mice showed significantly heavier 
body weight and BAT mass (Figure 4 and 13). Since ATGL mRNA expression is 
abundant in BAT and the ATGL KO mice generated by crossing Atgl fl/fl mice with Ap2-
-Cre (ASKO) also showed white-like BAT phenotype, dramatic increase in BAT mass is 
expected (Ahmadian et al., 2011; Kershaw et al., 2006). Unaltered PGAT weight, 
however, is a surprising finding because PGAT also highly expresses Atgl as compare to 
other organs (Kershaw et al., 2006). Consistently, we found no effect in PGAT mass of 
obese AAKO animals as compare to obese control PGAT (Figure 13). Since Wu et al. 
showed that ASKO mice have increase in Hsl expression and autophagy marker, LC3, in 
white adipose tissue during fasting (Wu et al., 2012), lack of PGAT ATGL perhaps 
resulted in compensatory response by stimulating HSL activity or autophagic lipid 
metabolism in adipocytes to overcome the overload of TG storage in the PGAT of 
AAKO mice. Another plausible reason is that since HSL KO mice showed increased LpL 
activity in adipose tissue (Haemmerle, Zimmermann, Strauss, et al., 2002), the genetic 
ablation of ATGL may have increased LpL activity as a compensatory mechanism and 




       One other potential explanation to the unaltered PGAT phenotype is that other 
cellular sources of ATGL may have compensated the lack of ATGL in PGAT. Because 
ASKO showed phenotype of significant increase in PGAT mass in obese mice, the other 
cellular sources of ATGL, such as macrophage-derived ATGL (Radovic, Aflaki, & 
Kratky, 2012), in adipose tissue may have contributed largely to total PGAT ATGL 
activity in AAKO mice. Additionally, in the point of developmental view, as PGAT 
hyperplasia has been shown essential during the development of obesity (Q. A. Wang et 
al., 2013), deletion of ATGL in PGAT may have lead to massive adipocyte death due to 
excessive TG load and in turn, it may have actively increased proliferation or 
differentiation of adipocytes, which probably normalized the total AAKO PGAT weight 
as in control PGAT weight in obese animals.  
        Unlike PGAT phenotype in AAKO mice, SCAT mass in lean AAKO mice were 
significantly bigger than control lean SCAT mass (Figure 4 and Figure 14), whereas 
SCAT mass in obese AAKO mice were smaller than control obese SCAT weight (Figure 
13). Since Wang et al. demonstrated that hypertrophic function in SCAT is dominant 
during pre- and post-natal developmental period and the onset of obesity (Q. A. Wang et 
al., 2013), increase of SCAT mass in lean AAKO mice is expected. However, significant 
reduction of SCAT weight in obese AAKO mice needs to be clarified. Because SCAT 
minimally undergo de novo adipogenesis as in PGAT, continuous feeding of a high-fat 
diet may have lead to overloading of TG, which perhaps resulted in extensive adipocyte 
death, and decreased total mass of SCAT in obese AAKO mice. Therefore, examination 
of adipocyte death in SCAT by doing TUNEL staining or measuring inflammatory- or 




reduction in SCAT mass. It can perhaps also be due to active compensation of other 
lipases in the SCAT and reduced the total SCAT volume during the long term high fat 
feeding. 
        To specifically explore our question of ATM subpopulations and its lipid content, 
we performed FACS to analyze FBs, FBCs, and their neutral lipid content in PGAT of 
both lean and obese mice. We found reduction of FBs but increase of FBCs in lean 
AAKO mice as compare to FBs and FBCs in control lean mice (Figure16). However, we 
observed decrease in total bodipy content in both FBs and FBCs in lean AAKO mice 
(Figure 17), suggesting that in lean animals, lipolysis regulates total lipid content in 
ATMs independent of CD11c+ ATMs. In contrast, in obese AAKO mice, we discovered 
that the percentage of FBs are higher but the percentage of FBCs are lower as compare to 
control AAKO mice, implying massive infiltration of ATMs in AAKO PGAT, which 
perhaps due to dynamic adipocyte turn-over in obese PGAT. Consistent with lower FBC 
content in obese AAKO mice, the total neutral lipid deposition was significantly lower in 
the obese AAKO mice. These data indicate that CD11c expressing ATMs are not directly 
regulated by lipid content in lean adipose tissue, whereas CD11c antigen presentation is 
associated with ATM lipid metabolism in obese adipose tissue. The future study needs to 
be designed to delineate the mechanism and complex reason of CD1lc expressing ATMs. 
         In conclusion, generation of adipocyte-specific ATGL KO mouse model showed 
depot specific effect of ATGL, which depends on nutritional status. The reason of 
unaltered PGAT mass needs to be more specifically addressed in the future study by 
measuring other lipase expression and activities and potential adipocyte turnovers. 




to be clearly explored as a part of future plan by analyzing SCAT histology and 
measuring adipocyte death. Of our interest, we explored the phenotype of ATMs in the 
AAKO mice. Our finding of significant reduction in total neutral lipid content in FBs and 
FBCs in both lean and obese AAKO mice exhibits that ATGL-dependent lipolysis 
regulates ATM lipid uptake in PGAT. However, the reason for the increased in FBC 
content in lean AAKO mice is still a question since we predicted CD11c+ as a marker for 
lipid-laden ATMs. As previously studied, it can be that CD11c+ is a marker for 
inflammatory ATMs, but at the same time, a marker for lipid-laden ATMs as well. As 
part of our future plan, investigating whether FBCs in AAKO mice have alteration in 
activation of lysosomal-dependent program would further define the function of ATMs in 
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Chapter 4: Conclusions and Future Directions 
4.1 Conclusions 
Obesity is associated with ATM accumulation, which eventually contributes to 
systemic inflammation and insulin resistance (Hotamisligil, 2006; Lumeng et al., 2007; 
Lumeng & Saltiel, 2011; Weisberg et al., 2003; H. Xu et al., 2003). Although the 
inflammatory phenotype of ATMs has been well studied, non-inflammatory function of 
ATMs is poorly defined. However, the trophic functions of macrophages are diverse and 
critical for development and function of many tissues and organs, including breast 
development, pituitary function and bone homeostasis (K. D. Nguyen et al., 2011; 
Pollard, 2009). The functions of ATMs are perhaps more complex than the inflammatory 
as literature would suggest. Indeed, our recent study showed that obesity induces a 
lysosome-related program required for normal lipid metabolism in ATMs and whole 
adipose tissue, a program that is independent of any classically defined inflammatory 
state. (X. Xu et al., 2013). My studies focused on  defining the function of a classical 
trophic factor, IGF1 and the role of adipocyte lipolysis in regulating ATMs.  
        In chapter 2, we undertook studies to determine whether ATM-derived or adipocyte-
derived IGF1 regulates adipose tissue hypertrophy, hyperplasia or lipid metabolism. Only 
recent studies identified macrophages as a local source of IGF1 (Lalancette-Hebert et al., 
2007; Lu et al., 2011; Wynes & Riches, 2003). For example, in a study of muscle injury 
and wound healing, it has been shown that macrophage-derived IGF1 is important for the 
resolution of tissue damage (Lu et al., 2011). In addition, depletion or the prevention of 
recruitment of ATMs to adipose tissue increases the rate of adipose tissue lipolysis 




hypothesized that local production of a factor by ATMs might regulate lipolysis.  
Analysis of expression profiles of purified ATMs identified several candidate pathways 
and factors that might mediate anti-lipolytic effects, including FGF, prostaglandin 2E and 
IGF1. Given that the expression of IGF1 by ATMs was comparable to that of liver, we 
tested whether local production of IGF1 by ATMs contributed measurable to adipose 
tissue Igf1 expression, and found that it does in adipose tissue from obese animals but not 
lean animals.   
The expression of IGF1 by adipose tissue is maintained as animals become obese 
and is associated with a decrease in expression by adipocytes and an increase 
contribution from ATMs. Conditional deletion of IGF1 in adipocytes or macrophages in 
lean animals does not measurably effect adipose tissue development or systemic 
metabolism. This was somewhat unexpected given that deletion of IR and IGF1R in 
adipose tissue reduces fat mass. In obese animals, however, we hypothesized that ATMs 
would be a major source of IGF1 in adipose tissue. Despite the substantial contribution of 
ATM-derived Igf1 to adipose tissue expression in obese animals in which ATMs do not 
express Igf1 (Mac-IKO) had no measurable effects on adipose tissue mass, histology or 
lipid metabolism in the fed or fasted state. However, when we placed the obese Mac-IKO 
mice in a cold challenge for 3-4 hours, the weight of PGAT in obese Mac-IKO mice was 
approximately 80% of obese control PGAT, but no difference was observed in adipocyte 
size, suggesting the decrease in total adipocyte number in the obese Mac-IKO mice. 
These results exhibit the important role of local ATM-derived IGF1 in adipogenesis 




    Considering the adipocytes and pre-adipocytes are also important sources of IGF1 in 
adipose tissue, we generated Adipo-IGF1 KO (Adipo-IKO) mice, which showed a 
phenotype of ~40% decrease in obese Adipo-IKO PGAT weight as compare to control 
obese PGAT, but no alteration was found in adipocyte size, suggesting the critical role of 
adipocyte-derived IGF1 in adipose tissue development during a prolonged high fat 
feeding. Together, we discovered that the regulation of adipose tissue IGF1 is complex 
and the local function of adipose IGF1 is essential in adipose tissue development in depot 
specific manner under a tissue-remodeling stimulus.  
  In chapter 3, we studied the role of lipolysis in ATM lipid content and phenotype. Since 
ATGL has been discovered as the functionally crucial lipase in fat (Jenkins et al., 2004; 
Villena et al., 2004; Zimmermann et al., 2004), we generated AAKO to create an in vivo 
model that is in state of inhibition of fat-specific lipolysis. Since AAKO is a novel mouse 
model in our laboratory, we first examined metabolic phenotype and then analyzed ATM 
markers with the total lipid content. Although we did not find change in total mass of 
PGAT in both lean and obese AAKO mice, we found significant low lipid content in 
ATMs (both FBs and FBCs) in lean and obese AAKO mice as compare to ATMs in 
control mice. These results indicate that ATGL-dependent lipolysis modulates ATM lipid 
accumulation. 
          In conclusion, we demonstrated that ATM-derived IGF1 modulates either 
adipocyte differentiation/proliferation or potentially local lipolysis under an extreme 
stimulus of tissue remodeling. Because cold challenge induces adrenergic stimulus, one 
alternative way to physiologically mimic the cold challenge is to use CL 316, 243 to 




243 in lean and obese in Mac-IKO mice will further provides clearer function of ATM-
derived IGF1 in adipose tissue. Unlike our hypothesis, we also discovered that adipocyte-
derived IGF1 regulates adipogenesis during a prolonged high fat feeding. Therefore, 
these results reveal the important local function of IGF1 in adipose tissue hyperplasia. 
Independent from the local IGF1 study, we also showed that lipolysis largely contributes 
to ATM lipid uptake. Although the specific molecular mechanism of lipid uptake and the 
intracellular lipid trafficking & metabolism in the ATMs are still needs to be addressed, 
as we hypothesized, we confirmed that adipose tissue lipolysis is a critical factor for 
ATM lipid accumulation.  
 
4.2- Local IGF1 production in adipose tissue and futures studies 
Our findings reveal several unexpected aspects of IGF1 regulation and function in 
adipose tissue. We unexpectedly found that while the expression of whole adipose tissue 
remains constant as mice become obese, the expression by relative contribution of Igf1 
expression by ATMs, adipocytes and what are likely pre-adipocytes change substantially.  
How Igf1 expression is maintained remains unknown. However, studies of targeted 
deletion of the IGF1R suggests that there is an out regulatory feedback loop (Kloting et 
al., 2008). In high fat fed animals in which the deletion of the IGF1R was driven by the 
aP2 promoter (a line which directs Cre-recombinase activity to adipocytes and ATMs) 
adipose tissue mass increased and was associated with a doubling of Igf1 expression by 
adipose tissue and an increase in circulating IGF1 protein (Kloting et al., 2008). Taken 
together with our data on the regulation of Igf1 expression, we hypothesize that deletion 




that Igf1 expression increases as macrophage content increases. With current genetic 
tools this hypothesis is testable.  These findings also raise the possibility that for other 
secreted factors adipocytes and ATMs may also work in concert to regulate whole 
adipose tissue IGF1 production.   
Another finding not completely aligned with our hypotheses was the  discovery 
that local IGF1 in adipose tissue can regulate adipocyte hyperplasia, but not appear to 
affect hypertrophy and that the effects are limited to the intra-abdominal PGAT depot..   
There are two possible ways in which IGF1 can increase adipocyte numbers – by 
increasing the generation (proliferation and differentiation) of adipocytes or by reducing 
turnover (apoptosis). To explore these possibilities, transgenic mouse models can be used 
that overexpress IGF1 in macrophages or adipocytes.  In these mice analysis of PGAT 
mass, and adipocyte number and size will help determine whether IGF1 is sufficient to 
drive differentiation and proliferation of adipocytes . If IGF1 overexpression in adipose 
tissue does increase PGAT mass and adipocyte number then assessing whether pre-
adipocyte pool is regulated by IGF1 would be the next question to answer IGF1 (Figure 
1).  
To address this question, the future experiment will take advantage of methods 
that identify adipocyte progenitor cells. Previous studies (Church et al., 2014; Rodeheffer 












Figure 2. Schematic diagram of the FACS strategy to isolate adipocyte progenitor 
cells (Cd24+) 







for the isolation of distinct cell populations on the basis of the
differential expression of previously characterized cell-surface
markers expressed by stem cell populations in other tissues.
Populations of individual cells were first sorted on the basis of
their expression of CD29 (b1-integrin) and CD34, both of which
are expressed by several stem cell populations (Shackleton
et al., 2006; Trempus et al., 2003; Wilson et al., 2007). Four pop-
ulations were isolated: CD29!:CD34! (P1), CD29lo:CD34! (P2),
CD29lo:CD34+ (P3), and CD29hi:CD34+ (P4). Sorted cells were
plated and grown to confluence, and the adipogenic potential
of these sorted populations (P1–P4) was analyzed in vitro by oil
red O staining. The induction of adipocyte differentiation was
tested through the use of a standard protocol for adipogenesis
that employs a cocktail of insulin, glucocorticoids, and isobutyl-
methylxanthine (IBMX) (see the Experimental Procedures). Only
the P3 fraction of CD29hi:CD34+ cells showed significant differ-
entiation in vitro, with accumulation of cells displaying unilocular
lipid droplets (Figure S1 available online).
Having established that there was a subpopulation of cells in
adipose stroma that was capable of differentiating into adipo-
cytes in vitro, we next performed FACS for additional cell surface
to further purify the adipogenic subpopulations. The strategy
that was used in these studies is shown (see Figure 1) and
described below. First, endothelial cells and hematopoietic cells
were depleted from the SVF on the basis of staining of CD31,
CD45, and Ter119, generating a lineage-negative (Lin!) popula-
tion. This step removed "25% of the cells in the SVF. Second,
the cell populations depleted of the lineage markers were sepa-
rated on the basis of staining for CD34 and CD29, as described
above. The Lin!:CD34+:CD29+ subpopulation was further sepa-
rated on the basis of staining for stem cell antigen 1 (Sca-1) and
CD24 (Figure 1 and Figure 2A), two cell-surface proteins that are
expressed on stem cell populations from other tissues (Shackle-
ton et al., 2006; Spangrude et al., 1988; Wilson et al., 2007).
The Lin!:CD29+:CD34+:Sca-1+ (Sca-1+) population comprises
approximately half of the cells present in the SVF (53.5%), but
only a small population of cells also expressed CD24 with the
total number of Lin!:CD29+:CD34+:Sca-1+:CD24+ (CD24+) cells
constituting in total"0.08% of the cells in the SVF (see Figure 1).
The Sca-1+ population was negative for CD105 (endoglin) and
CD117 (c-kit) (data not shown), distinguishing these cells from
bone marrow-derived mesenchymal stem cells and hematopoi-
etic stem cells (Li and Johnson, 1995; Sun et al., 2003).
We next tested whether the CD24+, Lin!:CD29+:CD34+:
Sca-1+:CD24! (CD24!) and Lin!:CD29+:CD34! (CD34!)
subpopulations can differentiate into adipocytes in vitro via the
aforementioned protocol. We found that after exposure to an
adipogenic cocktail in vitro, both the CD24+ and CD24! popula-
tions developed into adipocytes with large, unilocular lipid
droplets that stain with oil red O (Figure 2B). Similar levels of dif-
ferentiation of both the CD24+ and CD24! subpopulations were
also observed when insulin alone was substituted for the full adi-
pogenic hormone cocktail (data not shown). RT-PCR analysis of
mRNAs derived from these differentiated adipocytes showed an
approximately 7-fold increase in the expression of aP2 in both
the CD24+ and CD24! cultures versus the undifferentiated
populations. Expression of Adipsin was increased 5-fold in the
CD24! population and 25-fold in the CD24+ population
(Figure 2C). The 5-fold greater induction of Adipsin expression
in the CD24+ versus CD24! adipocytes suggested that these
are functionally distinct populations (confirmed in vivo, see
below). Although both CD24! and CD24+ populations could
robustly differentiate into adipocytes, the CD34! cells failed to
differentiate in response to the same adipogenic cocktail. Fur-
ther experiments showed that the CD24! and CD24+ cell popu-
lations are also capable of differentiating into bone, cartilage,
and muscle in vitro (Figure S2). In addition, although the unfrac-
tionated SVF showed some ability to differentiate into adipo-
cytes, it did so poorly when compared to the CD24! and
CD24+ populations, displaying significantly smaller numbers of
oil red O positive cells with multilocular lipid accumulation
(Figure 2B) and lower levels of Adipsin and aP2 expression
(Figure 2C). The finding that the SVF is poorly adipogenic in com-
parison to the CD24! population, which represents 53.5% of the
SVF, suggested that there may be inhibitory factors present in
the unfractionated SVF. Quantification of the number of oil red
O-positive cells derived from each cultured cell population iso-
lated in the FACS sorting scheme revealed that the CD24! and
CD24+ were 24-fold and 19-fold enriched, respectively, for adi-
pocytes versus the unfractionated SVF (Table S1). The extent
of differentiation of the SVF in these experiments was similar to
that documented in previous studies (Boquest et al., 2005; Izad-
panah et al., 2006; Wagner et al., 2005). These data indicated
that the FACS strategy that was employed enriched for adipo-
cyte precursor cells.
Markers of Adipogenesis Are Induced in Lipodystrophic
White Adipose Tissue
We next tested whether the different stromal cell fractions could
reconstitute WAT in vivo by transplanting "50,000 donor cells
into recipient animals. However, we did not observe any differen-
tiation of either the CD24+ or CD24! subpopulation into
adipocytes after injection of "50,000 cells into adipose tissue
of wild-type mice. This suggested that the microenvironment
Figure 1. A Schematic Representation of the FACS Strategy
The scheme for the FACS analysis is shown as a dendrogram of the hierarchy
developed for cell sorting. The percentage yield of each population compared
to the starting number live singl ce ls d rived from the SVF is indicated. Re-
sults are shown as mean ± SD (n = 4).




             To determine whether adipocyte-derived IGF1 regulates proliferation of pre-
adipocytes in addition to differentiation, we would isolate the CD24+ cells from SVCs of 
PGAT from both obese control and obese Adipo-IKO mice. Subsequently, we would 
compare the percentage of total CD24+ cells in obese control versus obese Adipo-IKO 
mice. If the percentage of the total CD24+ cells is lower in obese Adipo-IKO mice 
compare to the CD24+ cells in obese control animals, then we would conclude that 
adipocyte-derived IGF1 is an important modulator of pre-adipocyte proliferation during 
the development of obesity. If, however, the number of CD24+ cells in control and 
Adipo-IKO mice is the same, then it would imply that local IGF1 mobilize is already 
present in pre-adipocytes for differentiation.  
One aspect unaddressed by our studies is the role of IGF1-binding proteins 
(IGFBPs).  IGFBPs non-covalently bind to IGF1 in the circulation thereby sequestering 
active IGF1.  They are thought to be important systemic regulators but are not known to 
be important in locally produced IGF1. In our expression profiles of adipose tissue we 
found only one expressed at appreciable levels: IGFBP4.  Its role in local tissues in 
sequestering IGF1 within a tissue is not known. Recent studies, though, have found that 
IGFBP4 binds and activates the Wnt receptor Fizzled8, and thereby, regulates 
cardiomyocyte development (Zhu et al., 2008). In this context IGF1 acts an inhibitor of 
Wnt signaling. Hence, one potential function is IGF1 independent action. Genetic 
reagents exist to probe the function of IGFBP4 in adipose tissue and its interaction both 
physically and function with locally produced IGF1.   
The aforementioned future experiments will further define the novel functions of 




Additionally, therapeutic approach can be established by targeting fat-specific IGF1 in 
obese patients. Although systemic glucose homeostasis was unaltered by deleting fat-
derived IGF1, maintaining normal adipose tissue development during obesity would be 
indispensible to prevent other potential clinical complications. 
 
 4.3- Adipocyte lipolysis, non-canonical release of lipids and future studies 
Consistent with our hypothesis we found that ATGL-dependent lipolysis 
modulates ATM lipid content in both lean and obese mice. Although the lipid content of 
CD11c+ (FBC) ATMs is much greater than CD11c- (FB) ATMs, we found that deletion 
of  adipocyte Atgl/Pnpla2 reduces lipid content of both FBs and FBCs in the basal fed 
state. Most surprising was the observation that in obese animals acute stimulation with a 
β3-adrenergic specific agonist increased lipid content of ATMs in a Atgl-independent 
manner.  This implies one of two possibilities:  1) In the absence of ATGL another 
neutral lipase eg HSL can induce lipolysis from adipocytes 2) Adrenergic stimulation in 
obesity activates a non-canonical system of lipid release from adipocytes. Either 
possibility would have important implications for understanding lipid regulation in 
obesity. HSL was originally described as being the primary lipase regulated by 
catecholamines but why it activation would lead to release of lipids in obese but not lean 
AAKO mice is not clear.  
As mentioned earlier neutral lipids in ATMs from obese mice are contained, at 
least partly, in membrane bound structures (Xu et al 2013) but how the lipid would get to 
such structure is not clear. If lipid is derived from FFAs released from adipocytes, the 




would be a novel pathway for lipid synthesis. Alternatively, ATMs may take up neutral 
lipids via endocytosis. The form that such lipid would take is not clear but recent work in 
our laboratory has revealed that adipocytes specifically produce exosomes, which may 
contain lipid.  If this is the case, the adrenergic regulation of adipocytes would provide a 
novel mechanism for lipid release from adipose tissue. If lipolysis dominantly modulates 
total lipid content in ATMs, our next question is whether the less lipid accumulation lead 
to changes in lysosomal biogenesis in ATMs. In order to examine the ATM lysosomal 
biogenesis, we should isolate FBs and FBCs from PGAT of WT and AAKO mice to 
measure lysosome-related gene expression as our previous work (X. Xu et al., 2013). 
Furthermore, we can label ATMs with LysoTracker (a fluorescent amine that 
accumulates in acidic cellular compartments) and bodipy to assess the total neutral lipids 
and the presentation of fused acidic ring around lipids.  We can corroborate any changes 
by measuring proteins associated with lysosomes, eg LAMP2, LIPA, CSTK, by Western 
blots of ATM extracts. We can also visualize lipolysis dependent lysosome accumulation 
by electron microscopy (EM) and compare AAKO and control mice. Considering our 
current model in which lipid accumulation triggers lysosomal biogenesis, we expect less 
activation of lysosome-related programs in ATMs from AAKO mice because of reduced 
lipid content.  
One other intriguing question left is whether Cd11c expression is directly 
associated with lipid-laden ATMs. Our data indicated that percentage of FBCs is not 
absolutely correlated with neutral lipid content because FBCs were higher in lean AAKO 
mice whereas FBCs were lower in obese AAKO mice as compare to control counterparts, 




Chapter 3). Our current data suggest complex dynamics and plasticity of CD11c 
expression in ATMs. As previously shown, CD11c+ ATMs represents inflammatory 
phenotype (Olefsky & Glass, 2010; Patsouris et al., 2008), but simultaneously denotes 
lipid content of ATMs depending on microenvironment of adipose tissue. Therefore, 
future studies are needed to determine the molecular mechanism of formation of FBCs 
and functional role of FBCs. 
          Another important question remains to be determined is the mechanism of lipid 
transport and lipid trafficking in ATMs. Although the role of autophagy is a critical 
regulator of foam cells and hepatic lipid metabolism (Singh 2009), autophagy in ATMs 
does not contribute to lipid metabolism (X. Xu et al., 2013). So, we can eliminate one 
potential lipid metabolic pathway. Then the questions are; do the ATMs uptake FFA 
through classical lipid transporters such as Cd36 and Msr1 or do the ATMs simply utilize 
phagocytosis? If both transporter pathway and phagocytosis of lipid is important, then 
which mechanism is more dominant pathway in obesity? To test whether ATMs uptake 
lipid through lipid transporters, we should employ genetic model that lacks Cd36 in 
myeloid cells (Febbraio, Guy, & Silverstein, 2004) or Msr1 by doing bone marrow 
transplantation into ob/ob mice and measure the ATM markers and ATM lipid content as 
we mentioned in the Chapter 3. To assess whether ATMs uptake lipids in phagocytosis, 
we should isolate FBCs from WT and obese mice and do phagocytosis assay. 
         In conclusion, although we showed that lipolysis modulates ATM lipid ingestion, 
there are many questions yet to be determined to further delineate the lipid metabolism in 
ATMs. Future research needs to be focused to investigate mechanisms of lipid 




Nevertheless, our recent finding and our current data extended the notion of homeostatic 
function of ATMs, where the inflammatory role of ATMs is a restrictive description to 
the complex and dynamic function of ATMs in obesity. Therefore, this study will 
enhance to further understand the physiological and pathophysiological ontogeny of 
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